Search Result

Results for "

insulin

" in MCE Product Catalog:

By Targets:	IGF-1R (22) Insulin Receptor (52) 11β-HSD (1) 5-HT Receptor (1) Acyltransferase (2) Adenosine Kinase (1) Adenosine Receptor (1) Adenylate Cyclase (2) Adrenergic Receptor (2) Akt (7) Aldose Reductase (1) Amino Acid Derivatives (1) Aminopeptidase (2) AMPK (10) Amylin Receptor (7) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (2) Angiotensin Receptor (1) Angiotensin-converting Enzyme (ACE) (3) Antibiotic (2) Apelin Receptor (APJ) (2) Apoptosis (19) ATP Citrate Lyase (1) Autophagy (7) Bacterial (3) Bcl-2 Family (1) Biochemical Assay Reagents (2) Calcium Channel (3) Casein Kinase (1) CGRP Receptor (1) Cholecystokinin Receptor (1) CRFR (1) CXCR (1) Dipeptidyl Peptidase (9) DYRK (2) E1/E2/E3 Enzyme (1) EGFR (1) Endogenous Metabolite (10) ERK (2) Estrogen Receptor/ERR (1) FAK (1) FGFR (1) Free Fatty Acid Receptor (16) Fungal (1) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) G Protein-coupled Receptor Kinase (GRK) (1) GCGR (12) GLP Receptor (2) Glucocorticoid Receptor (3) Glucokinase (2) Glucosidase (5) GLUT (3) GPR119 (2) GSK-3 (1) HDAC (2) HIV (1) Imidazoline Receptor (1) Influenza Virus (1) Isotope-Labeled Compounds (4) Itk (1) JAK (2) JNK (1) Keap1-Nrf2 (1) Lactate Dehydrogenase (1) Liposome (1) mAChR (1) Melatonin Receptor (1) Mitochondrial Metabolism (3) Mitophagy (4) Monoamine Oxidase (2) Na+/K+ ATPase (1) NADPH Oxidase (2) Neuropeptide Y Receptor (2) NF-κB (2) NO Synthase (1) NOD-like Receptor (NLR) (3) Opioid Receptor (1) P2X Receptor (1) p38 MAPK (1) Parasite (3) PARP (1) PDGFR (1) Phosphatase (10) Phosphodiesterase (PDE) (2) Phospholipase (1) PI3K (4) PKA (3) Potassium Channel (9) PPAR (15) Proteasome (1) Proton Pump (2) PTEN (2) Pyk2 (1) RAR/RXR (1) Reactive Oxygen Species (8) Ribosomal S6 Kinase (RSK) (1) SARS-CoV (2) Ser/Thr Protease (1) SGLT (3) SHP2 (1) Small Interfering RNA (siRNA) (2) Sodium Channel (1) Somatostatin Receptor (5) STAT (1) Trace Amine-associated Receptor (TAAR) (1) TRP Channel (2) Tyrosinase (1)
By Research Areas:	Cancer (48) Cardiovascular Disease (24) Endocrinology (38) Infection (10) Inflammation/Immunology (35) Metabolic Disease (236) Neurological Disease (24)

By Targets:

IGF-1R (22)

Insulin Receptor (52)

11β-HSD (1)

5-HT Receptor (1)

Acyltransferase (2)

Adenosine Kinase (1)

Adenosine Receptor (1)

Adenylate Cyclase (2)

Adrenergic Receptor (2)

Akt (7)

Aldose Reductase (1)

Amino Acid Derivatives (1)

Aminopeptidase (2)

AMPK (10)

Amylin Receptor (7)

Amyloid-β (1)

Anaplastic lymphoma kinase (ALK) (2)

Angiotensin Receptor (1)

Angiotensin-converting Enzyme (ACE) (3)

Antibiotic (2)

Apelin Receptor (APJ) (2)

Apoptosis (19)

ATP Citrate Lyase (1)

Autophagy (7)

Bacterial (3)

Bcl-2 Family (1)

Biochemical Assay Reagents (2)

Calcium Channel (3)

Casein Kinase (1)

CGRP Receptor (1)

Cholecystokinin Receptor (1)

CRFR (1)

CXCR (1)

Dipeptidyl Peptidase (9)

DYRK (2)

E1/E2/E3 Enzyme (1)

EGFR (1)

Endogenous Metabolite (10)

ERK (2)

Estrogen Receptor/ERR (1)

FAK (1)

FGFR (1)

Free Fatty Acid Receptor (16)

Fungal (1)

FXR (1)

G protein-coupled Bile Acid Receptor 1 (1)

G Protein-coupled Receptor Kinase (GRK) (1)

GCGR (12)

GLP Receptor (2)

Glucocorticoid Receptor (3)

Glucokinase (2)

Glucosidase (5)

GLUT (3)

GPR119 (2)

GSK-3 (1)

HDAC (2)

HIV (1)

Imidazoline Receptor (1)

Influenza Virus (1)

Isotope-Labeled Compounds (4)

Itk (1)

JAK (2)

JNK (1)

Keap1-Nrf2 (1)

Lactate Dehydrogenase (1)

Liposome (1)

mAChR (1)

Melatonin Receptor (1)

Mitochondrial Metabolism (3)

Mitophagy (4)

Monoamine Oxidase (2)

Na+/K+ ATPase (1)

NADPH Oxidase (2)

Neuropeptide Y Receptor (2)

NF-κB (2)

NO Synthase (1)

NOD-like Receptor (NLR) (3)

Opioid Receptor (1)

P2X Receptor (1)

p38 MAPK (1)

Parasite (3)

PARP (1)

PDGFR (1)

Phosphatase (10)

Phosphodiesterase (PDE) (2)

Phospholipase (1)

PI3K (4)

PKA (3)

Potassium Channel (9)

PPAR (15)

Proteasome (1)

Proton Pump (2)

PTEN (2)

Pyk2 (1)

RAR/RXR (1)

Reactive Oxygen Species (8)

Ribosomal S6 Kinase (RSK) (1)

SARS-CoV (2)

Ser/Thr Protease (1)

SGLT (3)

SHP2 (1)

Small Interfering RNA (siRNA) (2)

Sodium Channel (1)

Somatostatin Receptor (5)

STAT (1)

Trace Amine-associated Receptor (TAAR) (1)

TRP Channel (2)

Tyrosinase (1)

By Research Areas:

Cancer (48)

Cardiovascular Disease (24)

Endocrinology (38)

Infection (10)

Inflammation/Immunology (35)

Metabolic Disease (236)

Neurological Disease (24)

301

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Insulin Receptor IGF-1R

Cat. No.	Product Name	Target	Research Areas

HY-P4062

Insulin peglispro BIL	Insulin Receptor	Metabolic Disease
Insulin peglispro (BIL) is a basal insulin with a flat, prolonged activity profile. Insulin peglispro can exhibit better glycaemic control compared to conventional insulins.

HY-108719

Insulin glargine
Insulin Receptor Metabolic Disease

Insulin glargine is a long-acting insulin analog. Insulin glargine can be used for the diabetes mellitus.

Insulin glargine	Insulin Receptor	Metabolic Disease
Insulin glargine is a long-acting insulin analog. Insulin glargine can be used for the diabetes mellitus.

HY-108743

Insulin degludec	Insulin Receptor	Endocrinology
Insulin degludec is an ultra-long-acting form of *insulin* used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC₅₀ value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.

HY-109556

Insulin Detemir	Akt ERK	Metabolic Disease
Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research.

HY-109530

Insulin lispro	Others	Metabolic Disease
Insulin lispro is a recombinant human insulin analogue and is one of three rapid-acting insulin analogues available. Insulin lispro can be used for the research of hyperglycaemia in diabetes mellitus.

HY-P1156

Insulin(cattle) insulin from bovine pancreas	Insulin Receptor	Metabolic Disease Endocrinology
Insulin cattle (Insulin from bovine pancreas) is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.

HY-108767

Insulin aspart B28Asp; B28-Asp-insulin; INA-X 14; insulin X 14	Insulin Receptor	Metabolic Disease
Insulin aspart (B28Asp) is a fast-acting analog of human insulin. Insulin aspart provides more rapid absorption than regular human insulin after subcutaneous administration. Insulin aspart can be used for researching diabetes.

HY-109555

Insulin glulisine HMR 1964	Insulin Receptor	Metabolic Disease
Insulin glulisine (HMR 1964) is a rapid-acting insulin analogue, it mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin. Insulin glulisine can be used for the research of diabetes.

HY-P0035

Insulin (human)
Insulin Receptor Metabolic Disease Endocrinology

Insulin (human) is a polypeptide hormone that regulates the level of glucose.
HY-112819

Insulin levels modulator
Insulin Receptor Metabolic Disease Endocrinology

Insulin levels modulator could be used to treat diabetes.

Insulin (human)	Insulin Receptor	Metabolic Disease Endocrinology
Insulin (human) is a polypeptide hormone that regulates the level of glucose.

Insulin levels modulator	Insulin Receptor	Metabolic Disease Endocrinology
Insulin levels modulator could be used to treat diabetes.

HY-P99665

Insulin efsitora alfa LY-3209590	Insulin Receptor	Metabolic Disease
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes.

HY-P4061

Insulin-like growth factor II IGF-II; IGF-2	IGF-1R	Metabolic Disease Neurological Disease
Insulin-like growth factor II (IGF-2) is the principal somatomedin of human serum. Insulin-like growth factor II exerts permissive and direct effects on neurite outgrowth and enhances survival of sympathetic and sensory neurons.

HY-P1773A

IGF-I (30-41) (TFA) insulin-like Growth Factor I (30-41) (TFA)	IGF-1R	Metabolic Disease Inflammation/Immunology
IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).

HY-P1777

IGF-I (24-41) insulin-like Growth Factor I (24-41)	IGF-1R	Metabolic Disease Inflammation/Immunology
IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) is amino acids 24 to 41 fragment of IGF-I. IGF-I, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I is partly responsible for systemic growth hormone (GH) activities. IGF-I has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) regulates somatic growth and behavioral development.

HY-P1777A

IGF-I (24-41) (TFA) insulin-like Growth Factor I (24-41) (TFA)	IGF-1R	Metabolic Disease Inflammation/Immunology
IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) TFA is amino acids 24 to 41 fragment of IGF-I. IGF-I TFA, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I TFA is partly responsible for systemic growth hormone (GH) activities. IGF-I TFA has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) TFA regulates somatic growth and behavioral development.

HY-P1776

*[pTyr1146][pTyr1150][pTyr1151]Insulin* Receptor (1142-1153)**	Insulin Receptor	Metabolic Disease
[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates.

HY-110197

6bK TFA	Others	Metabolic Disease
6bK TFA is a potent and selective insulin degrading enzyme (IDE) inhibitor with an IC₅₀ value of 50 nM. 6bK TFA increases circulating insulin in high-fat-fed mice. Acute administration of 6bK TFA enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice.

HY-B0089

Acarbose BAY g 5421	Glucosidase	Metabolic Disease
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC₅₀=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin.

HY-144752

cSPM Cyclic spermine	Amyloid-β	Neurological Disease
cSPM (Cyclic spermine) is a Aβ42 inhibitor. cSPM could suppress the aggregation of three different peptides, Aβ42, amylin and insulin, and decreases cytotoxicity.

HY-35028

Boc-Glu-Ofm
Amino Acid Derivatives Others

Boc-Glu-Ofm is a peptide. Boc-Glu-Ofm has been used for the synthesis of ester insulin and cyclic peptide mixtures.
HY-147394

GPR41 agonist-1
Others Metabolic Disease

GPR41 agonist-1 (compound 9) is a potent GPR41 agonist. GPR41 agonist-1 can be used for researching insulin-related disorders.

Boc-Glu-Ofm	Amino Acid Derivatives	Others
Boc-Glu-Ofm is a peptide. Boc-Glu-Ofm has been used for the synthesis of ester insulin and cyclic peptide mixtures.

GPR41 agonist-1	Others	Metabolic Disease
GPR41 agonist-1 (compound 9) is a potent GPR41 agonist. GPR41 agonist-1 can be used for researching insulin-related disorders.

HY-126125

CHIR-98023	GSK-3	Metabolic Disease Neurological Disease
CHIR-98023 is a potent, selective and reversible inhibitor of GSK3, with IC₅₀s of 10 nM and 6.7 nM for GSK3α and GSK3β, respectively. CHIR-98023 can improve insulin action and glucose metabolism.

HY-10524

GSK1904529A	IGF-1R Insulin Receptor Apoptosis	Cancer Endocrinology
GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC₅₀s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC₅₀>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity.

HY-P4685

(Sar1,Ile4,8)-Angiotensin II	Angiotensin Receptor	Metabolic Disease
(Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β.

HY-115461

MID-1	Insulin Receptor	Metabolic Disease
MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake.

HY-15209S

Repaglinide D5 AG-EE 623ZW d₅	Potassium Channel	Metabolic Disease
Repaglinide-d₅ is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].

HY-101962

HNMPA	Insulin Receptor	Metabolic Disease
HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities

HY-147392

CXCR2 antagonist 8
CXCR Metabolic Disease

CXCR2 antagonist 8 is a potent and selective CXCR2 antagonist. CXCR2 antagonist 8 can be used for insulin resistance research.

CXCR2 antagonist 8	CXCR	Metabolic Disease
CXCR2 antagonist 8 is a potent and selective CXCR2 antagonist. CXCR2 antagonist 8 can be used for insulin resistance research.

HY-P3616

Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide	GCGR	Metabolic Disease
Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide is a biotin labeled glucagon-like peptide-1-(7-36). Glucagon-like peptide-1-(7-36) is a gastrointestinal peptide with antidiabetogenic activity, and can increase the release of insulin.

HY-15209

Repaglinide
AG-EE 623ZW
Potassium Channel Metabolic Disease Cancer

Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus.

Repaglinide AG-EE 623ZW	Potassium Channel	Metabolic Disease Cancer
Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus.

HY-P3255

DA-JC4	Insulin Receptor	Inflammation/Immunology Neurological Disease
DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways.

HY-N1995

Methylswertianin	Others	Metabolic Disease
Methylswertianin is an active constituent in Swertia punicea Hemsl, with anti-diabetic effect. Methylswertianin can abates type-2 diabetes, likely via the improvement of insulin resistance (IR).

HY-N3426

Kazinol B	NO Synthase Akt AMPK	Metabolic Disease
Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of nitric oxide (NO) production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research.

HY-107651

VU 0365114	mAChR	Metabolic Disease
VU 0365114 is a selective mAChR M₅ positive allosteric modulator, with an EC₅₀ of 2.7 μM, and >30 μM for M1, M2, M3 and M4 receptors. VU 0365114 increases insulin secretion stimulated by ACh in human β-cells.

HY-N9535

tert-OMe-byakangelicin	Others	Metabolic Disease
tert-OMe-byakangelicin is a coumarin that can enhances the adrenaline-induced lipolytic effect and inhibits insulin-stimulated triglyceride synthesis from glucose in fat cells.

HY-143401

Hit 1
Others Metabolic Disease

Hit 1 is an activator of ansulin degrading enzyme (IDE), with an EC₅₀ of 5.5 μM. Hit 1 can decrease glucose-stimulating insulin secretion.

Hit 1	Others	Metabolic Disease
Hit 1 is an activator of ansulin degrading enzyme (IDE), with an EC₅₀ of 5.5 μM. Hit 1 can decrease glucose-stimulating insulin secretion.

HY-121565

SaRI 59-801	Others	Endocrinology Metabolic Disease
SaRI 59-801 is an orally effective hypoglycemic compound. SaRI 59-801 decreases blood glucose in several species and to elevate plasma insulin in rats and mice.

HY-108022A

MSDC-0602K Azemiglitazone potassium	Insulin Receptor PPAR	Metabolic Disease
MSDC-0602K (Azemiglitazone potassium), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC₅₀ of 18.25 μM. MSDC-0602K modulates the mitochondrial pyruvate carrier (MPC). MSDC-0602K can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance. MSDC-0602K, an *insulin* sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide.

HY-N9326

Uralenol	Phosphatase	Metabolic Disease
Uralenol is a natural PTP1B inhibitor (IC₅₀=21. 5 μM) from Broussonetia papyrifera. PTP1B have been shown to play a major role in the dephosphorylation of the insulin receptor in many cellular and biochemical studies.

HY-112469

ERK Inhibitor II (Negative control)	ERK Insulin Receptor	Metabolic Disease
ERK Inhibitor II (Negative control) is an effective inhibitor of extracellular signal-regulated kinase (ERK). ERK Inhibitor II (Negative control) inhibits the activation of insulin receptor, which can be used in the study of diabetes.

HY-N8522

9,10-Dihydroxystearic acid	Others	Metabolic Disease
9,10-Dihydroxystearic acid is an oxidation product of oleic acid. 9,10-Dihydroxystearic acid can improve glucose tolerance and insulin sensitivity in KKAy mice.

HY-P3577

[Tyr0] Gastric Inhibitory Peptide (23-42), human	Insulin Receptor	Metabolic Disease
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research.

HY-107586

Demethylasterriquinone B1 DAQ B1; L-783281; Dimethylasterriquinone	Insulin Receptor Akt	Endocrinology
Demethylasterriquinone B1 is a selective insulin receptor activator. Demethylasterriquinone B1 stimulates tyrosine phosphorylation of the IR β subunit, and the activation of PIK3 and AKT.

HY-111254

GQ-16	PPAR	Metabolic Disease
GQ-16 is a moderate affinity ligand for the ligand-binding domain (LBD) of PPARγ, exhibiting a K_i of 160 nM. GQ-16 is an effective inhibitor of Cdk5-mediated phosphorylation of PPARγ. GQ-16 is a partial agonist of PPARγ with reduced adipogenic actions. GQ-16 promotes insulin Sensitization without weight gain.

HY-P3580

Acetyl Gastric Inhibitory Peptide (human) Human N-acetyl GIP	Insulin Receptor	Endocrinology Metabolic Disease
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity.

HY-W018499

(S)-2-Hydroxybutanoic acid	Endogenous Metabolite	Others
(S)-2-Hydroxybutanoic acid is the S-enantiomer of 2-Hydroxybutanoic acid. 2-Hydroxybutanoic acid, a coproduct of protein metabolism, is an insulin resistance (IR) biomarker.

HY-148598

Curcumin 5-8 CUR5-8	Apoptosis Autophagy	Metabolic Disease
Curcumin 5-8 (CUR5-8) is a potent and orally active naturally active curcumin (CUR) analog. Curcumin 5-8 inhibits lipid droplet formation. Curcumin 5-8 increases autophagy and inhibits Apoptosis. Curcumin 5-8 improves insulin resistance and insulin sensitivity.

HY-148235

TP-051	Free Fatty Acid Receptor	Metabolic Disease
TP-051 is a potent FFAR1 agonist with an K_i value of 16 nM for human FFAR1. TP-051 can increase insulin secretion in rat insulinoma cells. TP-051 can be used to research type 2 diabetes.

HY-109018A

Velagliflozin proline	SGLT	Metabolic Disease
Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.

HY-148247

BI-2081	Free Fatty Acid Receptor	Metabolic Disease
BI-2081 is a GPR40 (FFAR1) partial agonist (EC₅₀: 4 nM). BI-2081 induces glucose depending insulin secretion and reduces the plasma glucose concentration. BI-2081 can be used in the research of metabolic diseases, in particular diabetes type 2.

HY-B0422

Nateglinide A4166; Senaglinide	Potassium Channel Dipeptidyl Peptidase	Metabolic Disease
Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K⁺ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus.

HY-122682

SBI-993	Others	Metabolic Disease
SBI-993 is a SBI-477 analog with improved potency and suitable pharmacokinetic properties for in vivo bioavailability. SBI-993 stimulates insulin signaling by deactivating the transcription factor MondoA.

HY-N9410

Lysophosphatidylcholine 18:2 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC	Endogenous Metabolite	Metabolic Disease
Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment.

HY-108523

LG100754 UVI 2112	RAR/RXR	Metabolic Disease
LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR.

HY-P1124

AS2034178 free base	Free Fatty Acid Receptor	Metabolic Disease
AS2034178 free base, a specific and orally active GPR40 agonist, exhibits glucose-dependent insulin secretion enhancement. AS2034178 free base has potential for type 2 diabetes mellitus research.

HY-129707

AMG 837 hemicalcium	Free Fatty Acid Receptor	Metabolic Disease
AMG 837 hemicalcium is a potent, orally bioavailable and partial agonist of GPR40/FFA1. AMG 837 hemicalcium inhibits specific [³H]AMG 837 binding at the human FFA1 receptor with a pIC₅₀ of 8.13. AMG 837 hemicalcium could enhance insulin secretion and lower glucose levels in rodents.

HY-13967B

AMG 837 calcium hydrate	Free Fatty Acid Receptor	Metabolic Disease
AMG 837 calcium hydrate is a potent, orally bioavailable and partial agonist of GPR40/FFA1. AMG 837 calcium hydrate inhibits specific [³H]AMG 837 binding at the human FFA1 receptor with a pIC₅₀ of 8.13. AMG 837 calcium hydrate could enhance insulin secretion and lower glucose levels in rodents.

HY-15671

GKA50	Glucokinase	Metabolic Disease
GKA50 is a potent glucokinase activator (EC₅₀=33 nM at 5 mM glucose). GKA50 stimulates insulin release from mouse islets of Langerhans. GKA50 is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca²⁺-dependent modulator of insulin secretion. GKA50 shows significant glucose lowering in high fat fed female rats.

HY-B0422S

Nateglinide D5 A4166 d₅; Senaglinide d₅	Potassium Channel Dipeptidyl Peptidase	Metabolic Disease
Nateglinide-d₅ is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].

HY-101379A

8-Bromo-cGMP sodium	Calcium Channel	Neurological Disease Cardiovascular Disease
8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is a PKG (protein kinase G) activator. 8-Bromo-cGMP sodium significantly inhibits Ca²⁺ macroscopic currents and impairs insulin release stimulated with high K⁺. 8-Bromo-cGMP sodium has antinociceptive effects and results in vasodilator responses.

HY-14771

Imeglimin EMD 387008	Mitochondrial Metabolism Reactive Oxygen Species	Metabolic Disease
Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function.

HY-124097

HNMPA-(AM)3	Insulin Receptor	Metabolic Disease
HNMPA-(AM)3 is a cell-permeable and selective insulin receptor tyrosine kinase inhibitor analog of HNMPA. HNMPA-(AM)3 greatly inhibits the ability of prothoracicotropic hormone (PTTH) to activate ERK phosphorylation and stimulate ecdysteroidogenesis.

HY-15671A

GKA50 quarterhydrate	Glucokinase	Metabolic Disease
GKA50 quarterhydrate is a potent glucokinase activator (EC₅₀=33 nM at 5 mM glucose) and stimulates insulin release from mouse islets of Langerhans. GKA50 quarterhydrate is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca²⁺-dependent modulator of insulin secretion. GKA50 quarterhydrate shows significant glucose lowering in high fat fed female rats.

HY-101764

Lintitript SR 27897	Cholecystokinin Receptor	Metabolic Disease
Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC₅₀ of 6 nM and a K_i of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC₅₀ value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin.

HY-W017227

Alloxan hydrate	Proteasome	Metabolic Disease
Alloxan hydrate is a diabetogenic agent to induce diabetes. Alloxan hydrate is a proteasome inhibitor. Alloxan causes diabetes in experimental animals through its ability to destroy the insulin-secreting B-cells of the pancreas.

HY-P1123

MEDICA16	ATP Citrate Lyase Free Fatty Acid Receptor	Metabolic Disease
MEDICA16, an ATP-citrate lyase inhibitor, significantly reduces intracellular TG content in gastrocnemius muscle, and this reduction is accompanied by an increase in insulin sensitivity. MEDICA16 is a selective agonist for GPR40 as well as selective partial agonists for GPR120.

HY-W145497

D-(+)-Sorbose	Insulin Receptor	Metabolic Disease
D-(+)-Sorbose, an active enantiomer of D-Sorbose, which inhibits disaccharidase activity and demonstrates suppressive action on postprandial blood levels of glucose and insulin in the rat. D-sorbose acts as a sweetener may contribute to the prevention of lifestyle-related diseases, such as type 2 diabetes mellitus.

HY-P0276

GIP, human Gastric Inhibitory Peptide (GIP), human	Insulin Receptor	Metabolic Disease
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion.

HY-N1419

Vaccarin	AMPK	Metabolic Disease
Vaccarin is an active flavonoid glycoside associated with various biological functions. Vaccarin significantly promote wound healing and endothelial cells and fibroblasts proliferation in the wound site. Vaccarin ameliorates insulin resistance and steatosis by activating the AMPK signaling pathway.

HY-P0276A

GIP, human TFA Gastric Inhibitory Peptide (GIP), human TFA	Insulin Receptor	Metabolic Disease
GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of *glucose-dependent insulin* secretion** and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion.

HY-N1743

1-(4-Hydroxy-2-methoxyphenyl)-3-(4-hydroxy-3-prenylphenyl)	Phosphatase	Metabolic Disease
1-(4-Hydroxy-2-methoxyphenyl)-3-(4-hydroxy-3-prenylphenyl), isolated from Broussonetia kazinoki, shows in vitro inhibition of protein tyrosine phosphatase 1B (PTP1B) with an IC₅₀ of 13.00 μM. PTP1B is a negative regulator of insulin action and an important mediator in the pathogenesis of insulinresistance and non-insulin dependent diabetes mellitus. PTP1B is regarded as a significant target for type 2 diabetes.

HY-103433

K579	Dipeptidyl Peptidase	Metabolic Disease
K579 is a potent and orally active dipeptidyl peptidase IV inhibitor. K579 inhibits the blood glucose elevation. K579 increases the plasma insulin and active forms of glucagon-like peptide-1 (GLP-1). K579 has the potential for the research of diabetic.

HY-N6181

Terrelumamide A	Others	Endocrinology
Terrelumamide A is a lumazine-containing peptide. Terrelumamide A is isolated from the culture broth of the marine-derived fungus Aspergillus terreus. Terrelumamide A exhibits pharmacological activity by improving insulin sensitivity. Terrelumamide A has the potential in the application of DNA sequence recognition.

HY-N9536

Cinnamtannin A2	GLP Receptor	Metabolic Disease
Cinnamtannin A2, a tetrameric procyanidin, can increases GLP-1 and insulin secretion in mice. Cinnamtannin A2 could upregulate the expression of corticotrophin releasing hormone. Cinnamtannin A2 exhibits antioxidant, anti-diabetic and nephroprotective effect.

HY-17471A

Metformin hydrochloride 1,1-Dimethylbiguanide hydrochloride	AMPK Autophagy Mitophagy	Metabolic Disease Cardiovascular Disease
Metformin hydrochloride (1,1-Dimethylbiguanide hydrochloride) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin hydrochloride triggers autophagy.

HY-W040127

Peonidin 3-O-glucoside chloride	Insulin Receptor	Metabolic Disease
Peonidin 3-O-glucoside chloride, an anthocyanin, act as an insulin secretagogue. Peonidin 3-O-glucoside chloride can increase glucose uptake in HepG2 cells. Peonidin 3-O-glucoside chloride has the potential for type-2 diabetes comorbidities research.

HY-P1871A

Amylin (IAPP), feline TFA	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion.

HY-B1245

Salsalate Salicylsalicylic acid; Disalicylic acid	Reactive Oxygen Species	Inflammation/Immunology
Salsalate, a non-acetylated salicylate, is an effective antirheumatic agent that bypasses gastric absorption and also avoids cyclooxygenase inhibition. Salsalate has anti-inflammatory activity and reduces glucose levels, insulin resistance, and cytokine expression. Salsalate can be used in the research of type 2 diabetes.

HY-P3578

Gastric Inhibitory Polypeptide (1-30), porcine	Insulin Receptor	Endocrinology
Gastric Inhibitory Polypeptide (1-30), porcine lacks the C-terminal 12 amino acid residues of natural gastric inhibitory polypeptide (GIP), exhibits biologic activity by potentiating the release of insulin and somatostatin.

HY-116844

Glymidine Glidiazine	Others	Metabolic Disease
Glymidine (Glidiazine) is a hypoglycaemic agent. Glymidine is a lipid soluble sulphapyrimidine derivative. Glymidine appears to stimulate insulin release from pancreas. Glymidine is a possible alternative to the sulphonylureas and biguanides for the research of diabetes mellitus.

HY-P1871

Amylin (IAPP), feline	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion.

HY-14363

TUG-424	Free Fatty Acid Receptor	Metabolic Disease
TUG-424 is a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ of 32 nM. TUG-424 significantly increases glucose-stimulated insulin secretion at 100 nM. TUG-424 may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity.

HY-P1184

HNGF6A	Reactive Oxygen Species	Metabolic Disease Neurological Disease Cardiovascular Disease
HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo.

HY-B0627

Metformin 1,1-Dimethylbiguanide	AMPK Autophagy Mitophagy	Cancer Metabolic Disease Cardiovascular Disease
Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy.

HY-134656

BC1618	AMPK Mitophagy E1/E2/E3 Enzyme	Metabolic Disease Inflammation/Immunology
BC1618, an orally active Fbxo48 inhibitory compound, stimulates Ampk-dependent signaling (via preventing activated pAmpkα from Fbxo48-mediated degradation). BC1618 promotes mitochondrial fission, facilitates autophagy and improves hepatic insulin sensitivity.

HY-118203

SU4984	FGFR PDGFR Insulin Receptor	Cancer
SU4984 is a protein tyrosine kinase inhibitor, with an IC₅₀ of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer.

HY-119322

Tifenazoxide NN414	Potassium Channel	Metabolic Disease
Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective K^ATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis.

HY-100550

MSDC 0160 Mitoglitazone; CAY10415	Insulin Receptor Mitochondrial Metabolism	Neurological Disease Endocrinology
MSDC 0160 (Mitoglitazone) is a mitochondrial target of thiazolidinediones (mTOT)-modulating insulin sensitizer and a modulator of mitochondrial pyruvate carrier (MPC). MSDC 0160 is a thiazolidinedione (TZD) with antidiabetic and neuroprotective activities. MSDC 0160 has the potential for Alzheimer′s disease.

HY-129736A

P32/98	Dipeptidyl Peptidase	Metabolic Disease
P32/98 a potent inhibitor of dipeptidyl peptidase IV with a K_i value of 130 nM. P32/98 improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model.

HY-P1184A

HNGF6A TFA	Reactive Oxygen Species	Metabolic Disease Neurological Disease Cardiovascular Disease
HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo.

HY-136561

GRK5-IN-2	G Protein-coupled Receptor Kinase (GRK)	Metabolic Disease
GRK5-IN-2 (compound 707), a pyridine-based bicyclic compound, is a potent G-protein-coupled receptor kinase 5 (GRK5) inhibitor. GRK5-IN-2 regulates the expression and/or release of insulin and is useful for the metabolic disease research.

HY-108611

AACOCF3 Arachidonyl trifluoromethyl ketone	Phospholipase	Cardiovascular Disease
AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2). AACOCF3 blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. AACOCF3 inhibits glucose-induced insulin secretion from isolated rat islets. AACOCF3 has the potential for the research of cardiovascular disease.

HY-P0262

Galantide	Neuropeptide Y Receptor	Metabolic Disease Inflammation/Immunology Neurological Disease Endocrinology
Galantide, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (K_D<0.1 nM and ~6 nM) in the rat hypothalamus. Galantide dose dependently (IC₅₀=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide appears to bind to a single population of SP receptors (K_D~40 nM).

HY-129736

P32/98 hemifumarate	Dipeptidyl Peptidase	Metabolic Disease
P32/98 hemifumarateis a potent inhibitor of dipeptidyl peptidase IV with a K_i value of 130 nM. P32/98 hemifumarate improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model.

HY-108469

BI-6015	Others	Cancer Metabolic Disease
BI-6015 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BI6015 represses insulin promoter activity through HNF4α antagonism. BI-6015 can be used for the research of cancer and diabetes.

HY-19694

BRD7552	Others	Endocrinology
BRD7552, a potent PDX1 transcription factor inducer, upregulates PDX1 expression in both primary human islets and ductal cells, and induces epigenetic changes in the PDX1 promoter consistent with transcriptional activation. BRD7552 increases insulin expression. PDX1 is a key transcription factor involved in pancreas development and β cell function.

HY-14292

NVP-DPP728	Dipeptidyl Peptidase	Metabolic Disease
NVP-DPP728 is a potent, reversible and nitrile-dependent dipeptidyl peptidase IV (DPP-IV) inhibitor. NVP-DPP728 can inhibit human DPP-IV amidolytic activity with a K_i of 11 nM. NVP-DPP728 inhibits degradation of glucagon-like peptide-1 (GLP-1) and thereby potentiates insulin release in response to glucose intake. NVP-DPP728 can be used for researching diabetes.

HY-124424

VU0071063	Potassium Channel	Neurological Disease Others
VU0071063 is a potent and specific Kir6.2/SUR1 opener (EC₅₀=7.44 μM) and can be used for investigating Kir6.2/SUR1 expressed in the pancreas and brain. VU0071063 inhibits insulin secretion by inducing hyperpolarization of β-cell membrane potential. VU0071063 chemotype has a very steep structure-activity relationships.

HY-N10405

(R)-5-Hydroxy-1,7-diphenyl-3-heptanone	Keap1-Nrf2	Metabolic Disease
(R)-5-Hydroxy-1,7-diphenyl-3-heptanone is a diarylheptanoid that can be found in Alpinia officinarum. (R)-5-Hydroxy-1,7-diphenyl-3-heptanone ameliorates oxidative stress and insulin resistance via activation of Nrf2/ARE pathway.

HY-151959

FXR agonist 4	FXR	Metabolic Disease Inflammation/Immunology Cardiovascular Disease
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC₅₀ value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD).

HY-135897

Urolithin C	Calcium Channel Reactive Oxygen Species Apoptosis Endogenous Metabolite	Metabolic Disease
Urolithin C, a gut-microbial metabolite of Ellagic acid, is a glucose-dependent activator of insulin secretion. Urolithin C is a L-type Ca²⁺ channel opener and enhances Ca²⁺ influx. Urolithin C induces cell apoptosis through a mitochondria-mediated pathway and also stimulates reactive oxygen species (ROS) formation.

HY-P3019

Urocortin III (human)	CRFR	Endocrinology Neurological Disease Cardiovascular Disease
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) selectively binds to type 2 CRF receptors with K_i values of 13.5, 21.7, and >100 nM for mCRF2β, rCRF2α, and hCRF1, respectively. Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion.

HY-W337897

Tetradecyl-β-D-maltoside	Biochemical Assay Reagents	Metabolic Disease
Tetradecyl-β-D-maltoside is an absorption enhancer which can increase the nasal absorption of regular human insulin or the fast acting insulin analog lyspro-insulin.

HY-P2048A

MOTS-c(human) acetate	AMPK GLUT	Metabolic Disease
MOTS-c(human) acetate is a mitochondrial-derived peptide. MOTS-c(human) acetate induces the accumulation of AMP analog AICAR, increases activation of AMPK and expression of its downstream GLUT4. MOTS-c(human) acetate induces glucose uptake and improves insulin sensitivity. MOTS-c(human) acetate has implications in the regulation of obesity, diabetes, exercise, and longevity.

HY-N7073

Silymarin	SARS-CoV	Cancer Infection Inflammation/Immunology Neurological Disease
Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 main protease (M^pro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research.

HY-13682B

Mifamurtide sodium MTP-PE sodium; L-MTP-PE sodium; CGP 19835 sodium	NOD-like Receptor (NLR)	Cancer Inflammation/Immunology
Mifamurtide sodium (MTP-PE sodium), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide sodium, an orphan agent, is a specific ligand of NOD2 used as an insulin sensitizer. Mifamurtide sodium has the potential for osteosarcoma research.

HY-13682

Mifamurtide MTP-PE; L-MTP-PE; CGP 19835	NOD-like Receptor (NLR)	Cancer Inflammation/Immunology
Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide, an orphan agent, is a specific ligand of NOD2 used as an insulin sensitizer. Mifamurtide has the potential for osteosarcoma research.

HY-108020

LY2881835	Free Fatty Acid Receptor	Endocrinology
LY2881835 is a potent and selective agonist of G protein-coupled receptor 40 (GPR40). LY2881835 has efficacious and durable dose-dependent reductions in glucose levels along with significant increases in insulin and GLP-1 secretion. LY2881835 has the potential for the research of type 2 diabetes mellitus.

HY-112720

AGL-2263
Insulin Receptor Metabolic Disease Endocrinology

AGL-2263 is an insulin receptor and insulin-like growth factor (IGF) receptor inhibitor.

HY-107535

AS1269574	GPR119 TRP Channel	Metabolic Disease
AS1269574 is a potent, orally available GPR119 agonist, with an EC₅₀ of 2.5 μM in HEK293 cells expressing human GPR119. AS1269574 activates TRPA1 cation channels to stimulate glucagon-like peptide-1 (GLP-1) secretion. AS1269574 specifically induces glucose-dependent insulin secretion from pancreatic β-cells only under high-glucose conditions. AS1269574 has the potential for the research of type 2 diabetes.

HY-120327

KY-226	Phosphatase	Metabolic Disease Neurological Disease
KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC₅₀ of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury.

HY-13682C

Mifamurtide TFA MTP-PE TFA; L-MTP-PE TFA; CGP 19835 TFA	NOD-like Receptor (NLR)	Cancer Inflammation/Immunology
Mifamurtide TFA (MTP-PE TFA), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide TFA, an orphan agent, is a specific ligand of NOD2 used as an insulin sensitizer. Mifamurtide TFA has the potential for osteosarcoma research.

HY-118567

Bis(maltolato)oxovanadium(IV) BMOV	SHP2 Phosphatase	Metabolic Disease
Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC₅₀s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer.

HY-142295

GNF2133	DYRK	Metabolic Disease
GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes.

HY-142295A

GNF2133 hydrochloride	DYRK	Metabolic Disease
GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes.

HY-W037817

Dimethyl L-glutamate Dimethyl glutamate	Potassium Channel Bacterial	Infection Metabolic Disease
Dimethyl L-glutamate (Dimethyl glutamate), a membrane-permeable analog of Glutamate, can stimulate *insulin* release induced by Glucose. Dimethyl L-glutamate suppresses the K_ATP channel activities. Dimethyl L-glutamate inhibits E. gracilis growth and causes abnormal cell division. Dimethyl L-glutamate can be used in the research of diabetes, glucose transport, phosphorylation, and further metabolism.

HY-19618

BRD3308	HDAC HIV Apoptosis	Infection Metabolic Disease
BRD3308 is a highly selective HDAC3 inhibitor with an IC₅₀ of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC₅₀ of 1.26 μM) or HDAC2 (IC₅₀ of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency.

HY-18686

AS1949490	Phosphatase Akt	Metabolic Disease
AS1949490 is a potent, orally active, selective SHIP2 phosphatase inhibitor with IC₅₀ values of 0.34, 0.62, 13, >50, >50, and >50 µM for Mouse SHIP2, Human SHIP2, Human SHIP1, Human PTEN, Human synaptojanin, and Human myotubularin, respectively. AS1949490 increases the phosphorylation of Akt, glucose consumption and glucose uptake. AS1949490 activates intracellular insulin signalling pathways. AS1949490 can be used for research of diabetes.

HY-153335

Enpp-1-IN-16	Phosphodiesterase (PDE)	Cancer Infection Metabolic Disease Inflammation/Immunology Cardiovascular Disease
Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders.

HY-P3542

Des His1, Glu8 Exendin-4	GCGR	Metabolic Disease
Des His1, Glu8 Exendin-4 is a potent glucagon-like peptide-1 receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal.

HY-B0384

Temocapril hydrochloride	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.

HY-100713

Temocapril	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.

HY-19995

GSK137647A GSK 137647	Free Fatty Acid Receptor	Metabolic Disease
GSK137647A (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC₅₀ values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC₅₀ values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively. GSK137647A has anti-inflammatory activity. GSK137647A induces insulin secretion and inhibits epithelial ion transport, GSK137647A is related to regulation of glucose homeostasis and anti-inflammatory response.

HY-117656

ESI-05 NSC 116966	Acyltransferase	Metabolic Disease Neurological Disease
ESI-05 is a specific exchange proteins directly activated by cAMP 2 (EPAC2) inhibitor. ESI-05 inhibits cAMP-mediated EPAC2 GEF activity with an IC₅₀ of 0.43 μM. ESI-05 can be used for the research of diabetes, insulin secretion and neurological disorders.

HY-15589

GW9508	Free Fatty Acid Receptor Potassium Channel	Metabolic Disease Inflammation/Immunology Cardiovascular Disease
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC₅₀s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (K_ATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities.

HY-142663

OI338
Insulin Receptor Metabolic Disease

OI338 is an orally available, ultralong-acting insulin analogue.

HY-B0089A

Acarbose sulfate Bay-g 5421 sulfate	Glucosidase	Metabolic Disease
Acarbose (BAY g 5421) sulfate, antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC₅₀=11 nM). Acarbose sulfate can potentiate the hypoglycemic effects of sulfonylureas or insulin.

HY-N0457

Chicoric acid Cichoric acid; Dicaffeoyltartaric acid	Reactive Oxygen Species Apoptosis	Metabolic Disease Inflammation/Immunology
Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects.

HY-P0150

Glucagon (19-29), human
GCGR Neurological Disease

Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.

HY-B1021

Vincamine	Free Fatty Acid Receptor	Metabolic Disease Cardiovascular Disease
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation. Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research.

HY-121900

LT175	PPAR	Endocrinology Metabolic Disease
LT175, a dual PPARα/γ ligand, is an orally active partial agonist against PPARγ(hPPARα:EC₅₀=0.22 μm; mPPARα:EC₅₀=0.26 μm; hPPARγ:EC₅₀=0.48 μm). LT175 interacts with PPARγ and affects the recruitment of the coregulators cyclic-AMP response element-binding protein-binding protein and nuclear corepressor 1 (NCoR1). LT175 interacts with PPARγ in a hydrophobic region called “diphenyl pocket”. LT175 has potent insulin-sensitizing effects and reduced adipogenic properties.

HY-P2093

S961	Insulin Receptor	Metabolic Disease
S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC₅₀s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.

HY-P2093B

S961 acetate	Insulin Receptor	Metabolic Disease
S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC₅₀s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.

HY-U00259

BM152054
Others Metabolic Disease

BM152054 can promote glucose utilization in peripheral tissues by enhancing insulin action.

HY-P2093A

S961 TFA	Insulin Receptor	Metabolic Disease
S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC₅₀s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.

HY-B1429

Chlorpropamide
Na+/K+ ATPase Endocrinology

Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).

HY-P0054A

GLP-1(7-36), amide Glucagon-like peptide-1 (GLP-1)(7-36), amide; Human GLP-1 (7-36), amide	GCGR	Metabolic Disease
GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretion.

HY-10262

BMS-536924	IGF-1R Insulin Receptor Apoptosis	Cancer Endocrinology
BMS-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC₅₀s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity.

HY-110259

HFI-142
Aminopeptidase Neurological Disease

HFI-142 is an insulin-regulated aminopeptidase (IRAP) inhibitor with a K_i of 2.01 μM.
HY-P0055

GLP-1(7-37)
GCGR Metabolic Disease

GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

HY-P2080B

GIP (1-30) amide,human acetate	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human acetate dose-dependently promotes insulin secretion over the range 10^-9-10^-6 M.

HY-P2080

GIP (1-30) amide,human	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human dose-dependently promotes insulin secretion over the range 10^-9-10^-6 M.

HY-N3021

D-chiro-Inositol	Endogenous Metabolite	Metabolic Disease
D-chiro-Inositol is an epimer of myo-inositol found in certain mammalian glycosylphosphatidylinositol protein anchors and inositol phosphoglycans possessing insulin-like bioactivity. D-chiro-Inositol is used clinically for the treatment of polycystic ovary syndrome (PCOS) and diabetes mellitus, which can reduce hyperglycemia and ameliorate insulin resistance.

HY-17365

Octreotide acetate SMS 201-995 acetate	Somatostatin Receptor	Inflammation/Immunology Cardiovascular Disease Endocrinology Cancer
Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, glucagon, and *insulin* more potently.

HY-W010031

1-Methyluric acid	Endogenous Metabolite	Metabolic Disease
1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels.

HY-B0881

Acetohexamide	Others	Metabolic Disease Cancer
Acetohexamide is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2; stimulate the pancreas to secrete insulin.

HY-P0055A

GLP-1(7-37) acetate
GCGR Metabolic Disease

GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

HY-124418

SBI-477	Others	Metabolic Disease
SBI-477 is a chemical probe stimulated insulin signaling by deactivating the transcription factor MondoA, leading to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain–containing 4 (ARRDC4). SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes.

HY-14234

Glucocorticoid receptor agonist	Glucocorticoid Receptor	Endocrinology Metabolic Disease Inflammation/Immunology
Glucocorticoid receptor agonist is a Glucocorticoid receptor agonist that acts on Glucocorticoid receptor (GR), progesterone receptor (PR) and mineralocorticoid receptor (MR) with the IC₅₀ values of 2.1 , 1200 and 210 nM, respectively. Glucocorticoid receptor agonist has steroid-like anti-inflammatory properties and may be used to improve metabolism and reduce increased levels of body fat and serum insulin.

HY-139710

Glucocorticoids receptor agonist 2	Glucocorticoid Receptor	Inflammation/Immunology
Glucocorticoids receptor agonist 2 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.

HY-N0628

Kaempferitrin Lespedin; Lespenephryl	Insulin Receptor	Cancer Metabolic Disease Endocrinology
Kaempferitrin is a natural flavonoid, possesses antinociceptive, anti-inflammatory, anti-diabetic, antitumoral and chemopreventive effects, and activates *insulin* signaling pathway.

HY-139709

Glucocorticoids receptor agonist 1	Glucocorticoid Receptor	Inflammation/Immunology
Glucocorticoids receptor agonist 1 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.

HY-125588

Chromium picolinate Chromium (III) picolinate; Cr(Pic)3	Others	Metabolic Disease
Chromium picolinate (Chromium (III) picolinate) reduces insulin resistance and has the potential for type 2 diabetes mellitus.

HY-P3954

Somatostatin-28 (sheep)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion.

HY-P0054

GLP-1(7-36), amide acetate Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-Y1892

Gelucire 44/14	Biochemical Assay Reagents	Others
Gelucire 44/14 is a potential and safe absorption enhancer for improving the absorption of poorly absorbable agents including insulin and calcitonin by pulmonary delivery.

HY-15481

KU14R
Insulin Receptor Metabolic Disease Endocrinology

KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.
HY-153479

Aganirsen
Insulin Receptor Inflammation/Immunology

Aganirsen is a 25 mer DNA antisense oligonucleotide, which silences expression of insulin receptor substrate-1 (IRS-1).

HY-107544

8-pCPT-2'-O-Me-cAMP-AM	PKA	Metabolic Disease
8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates Epac-Rap signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway.

HY-15494

Picropodophyllin AXL1717; Picropodophyllotoxin; PPP	IGF-1R Apoptosis	Cancer Endocrinology
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-N2209

Angeloylgomisin H	PPAR	Metabolic Disease
Angeloylgomisin H, as a major lignin extract of Schisandra rubriflora, has the potential to improve insulin-stimulated glucose uptake by activating PPAR-γ.

HY-13967

AMG 837	Free Fatty Acid Receptor	Metabolic Disease
AMG 837 is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.

HY-13967A

AMG 837 sodium salt	Free Fatty Acid Receptor	Metabolic Disease
AMG 837 sodium salt is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.

HY-P0054B

GLP-1(7-36), amide TFA Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-P2542

GIP (3-42), human	Insulin Receptor	Metabolic Disease
GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo.

HY-N4244

Kakkalide	Reactive Oxygen Species	Inflammation/Immunology
Kakkalide is an isoflavone derived from the flowers of Pueraria lobata. Kakkalide ameliorates endothelial insulin resistance by suppressing reactive oxygen species (ROS)-associated inflammation.

HY-144873

AVJ16	Insulin Receptor	Cancer
AVJ16 is a member of the insulin-like growth factor 2 mRNA-binding protein family. AVJ16 regulates protein translation by binding to the mRNAs of certain genes.

HY-P1790

Axltide
JAK Metabolic Disease

Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases.

HY-18785

Indirubin Derivative E804	IGF-1R	Cancer Endocrinology
Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor (IGF1R), with an IC₅₀ of 0.65 μM for IGF1R.

HY-P1742

Gluten Exorphin B5	Opioid Receptor	Metabolic Disease
Gluten Exorphin B5 is an exogenous opioid peptides derived from wheat gluten, acts on opioid receptor, increases postprandial plasma insulin level in rats.

HY-B1726

Phenacaine Holocaine	Phosphodiesterase (PDE)	Metabolic Disease
Phenacaine (Holocaine) is a local anesthetic. Phenacaine inhibits the specific calmodulin-dependent stimulation of erythrocyte Ca²⁺-ATPase and cyclic nucleotide phosphodiesterases from brain and heart.

HY-125382

L-797591
Somatostatin Receptor Metabolic Disease

L-797591 is a selective somatostatin receptor subtype 1 (SSTR1) agonist.

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-13020

GSK1838705A	Anaplastic lymphoma kinase (ALK) IGF-1R Insulin Receptor	Cancer Endocrinology
GSK1838705A is a potent and reversible IGF-IR and the insulin receptor inhibitor with IC₅₀s of 2.0 and 1.6 nM, respectively. It also inhibits ALK with an IC₅₀ of 0.5 nM.

HY-N2118

Bilobetin	PPAR PKA	Metabolic Disease
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity.

HY-117878

ML345	Others	Metabolic Disease
ML345 is a potent and selective insulin-degrading enzyme (IDE) small-molecule inhibitor, with an IC₅₀ value of 188 nM. ML345 can be for use as a pharmacophore for agent development in diabetes research.

HY-10191

Linsitinib OSI-906	IGF-1R Insulin Receptor	Cancer Endocrinology
Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC₅₀s of 35 and 75 nM, respectively.

HY-128400

4'-Methoxychalcone	PARP	Metabolic Disease Cancer
4'-Methoxychalcone regulates adipocyte differentiation through PPARγ activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity.

HY-P1980

A-71915 TFA	Apoptosis	Metabolic Disease
A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells.

HY-U00462

D-Mannoheptulose	Others	Metabolic Disease
D-Mannoheptulose is a major non-structural carbohydrate in avocado. D-mannoheptulose is a specific inhibitor of D-glucose phosphorylation. D-Mannoheptulose can block insulin release and utilization of carbohydrate in rat.

HY-W030796A

Lactisole	Others	Metabolic Disease
Lactisole is a canonical antagonist of sweet taste receptor, selectively targeting to T1R3 subunit, a glucose-sensing receptor. Lactisole inhibits insulin secretion induced by glucose in mouse islets.

HY-P1473

Amylin (8-37), rat Amylin (8-37) (mouse, rat)	Amylin Receptor	Metabolic Disease
Amylin (8-37), rat is a truncated analog of native Amylin that selectively inhibits insulin-related glucose uptake and glycogen deposition in muscle tissue. Amylin (8-37), rat is a weak amylin receptor (AMY) antagonist.

HY-151518

Aminopeptidase-IN-1	Aminopeptidase	Neurological Disease
Aminopeptidase-IN-1 (compound 16o) is a potent insulin-regulated aminopeptidase (IRAP) inhibitor with an K_i value of 7.7 μM. Aminopeptidase-IN-1 can be used tor research cognitive and memory impairments.

HY-B0283A

Acipimox sodium K-9321 sodium	Others	Metabolic Disease
Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.

HY-B0283

Acipimox K-9321	Others	Metabolic Disease
Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.

HY-13525

CP-91149	Others	Cancer Metabolic Disease
CP-91149 is a GP (glycogen phosphorylase) inhibitor. CP-91149 promotes glycogen resynthesis, but not its overaccumulation. CP-91149 has the potential for Type II (insulin-dependent) diabetes study.

HY-P4860

Adropin (34-76) (human, mouse, rat)	Akt	Metabolic Disease
Adropin (34-76) (human, mouse, rat) regulates fuel selection preferences in skeletal muscle. Adropin increases insulin-induced Akt phosphorylation and cell-surface expression of GLUT4, in diet-induced obesity (DIO) mouse.

HY-P4785

Acetyl-Amylin (8-37) (human)
Amylin Receptor Metabolic Disease

Acetyl-Amylin (8-37) (human) is a specific amylin antagonist.

HY-N2421

Sequoyitol 5-O-Methyl-myo-inositol	Others	Metabolic Disease
Sequoyitol (5-O-Methyl-myo-inositol) is isolated from plants. Sequoyitol (5-O-Methyl-myo-inositol) decreases blood glucose, improves glucose intolerance, and is used to treat diabetes.

HY-B0401A

Tolbutamide sodium	Apoptosis	Metabolic Disease
Tolbutamide sodium is a potent and orally active antidiabetic agent. Tolbutamide sodium induces apoptosis in a Ca²⁺ dependent manner in pancreatic β-cells. Tolbutamide sodium has the potential for the research of non-insulin-dependent diabetes mellitus.

HY-110228

Metformin-d6 hydrochloride 1,1-Dimethylbiguanide-d₆ (hydrochloride)	AMPK Autophagy Mitophagy	Metabolic Disease Cardiovascular Disease
Metformin-d₆ (hydrochloride)e is a deuterium labeled Metformin hydrochloride. Metformin hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin hydrochloride triggers autophagy[1].

HY-U00462S

D-Mannoheptulose-13C	Isotope-Labeled Compounds	Metabolic Disease
D-Mannoheptulose-¹³C is the ¹³C labeled D-Mannoheptulose. D-Mannoheptulose is a major non-structural carbohydrate in avocado. D-mannoheptulose is a specific inhibitor of D-glucose phosphorylation. D-Mannoheptulose can block insulin release and utilization

HY-P1070

Amylin, amide, human DAP amide, human	Amylin Receptor	Metabolic Disease
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent.

HY-100713S

Temocapril-d5	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Temocapril-d₅ is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases[1][2].

HY-P99530

Valanafusp alfa AGT-181; HIRMAb-IDUA	Insulin Receptor	Metabolic Disease
Valanafusp alfa (AGT-181) is a brain penetrating recombinant fusion protein of a chimeric monoclonal antibody against the human insulin receptor (HIR) and human iduronidase (IDUA). Valanafusp alfa can be used for the research of Mucopolysaccharidosis type I (MPS I) .

HY-P1070A

Amylin, amide, human TFA DAP amide, human TFA	Amylin Receptor	Metabolic Disease
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent.

HY-112606

ML-290	Others	Others
ML-290 is a first-in-class and potent relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC₅₀ of 94 nM. ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.

HY-15494S1

Picropodophyllin-d6 AXL1717-d₆; Picropodophyllotoxin-d₆; PPP-d₆	Isotope-Labeled Compounds IGF-1R Apoptosis	Cancer Endocrinology
Picropodophyllin-d₆ (AXL1717-d₆) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-108905

Mecasermin Human IGF-I; FK 780	IGF-1R	Metabolic Disease
Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies.

HY-P2541

GIP (1-30) amide, porcine	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42). GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P99197

Figitumumab CP-751871	IGF-1R	Cancer
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC₅₀ of 1.8 nM.

HY-109018B

Velagliflozin proline hydrate	SGLT	Metabolic Disease
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.

HY-13896

PD168393	EGFR Autophagy Apoptosis	Cancer
PD168393 is a potent, selective and cell-permeable inhibitor of EGFR tyrosine kinase and ErbB2. PD168393 irreversiblely inactivates EGF receptor ( IC₅₀=0.7 nM) and is inactive against insulin receptor, PDGFR, FGFR and PKC.

HY-N2177

3-Dehydrotrametenolic acid	Lactate Dehydrogenase Apoptosis	Cancer
3-Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-Dehydrotrametenolic acid induces apoptosis and has anticancer activity.

HY-15564

AR 231453
GPR119 Metabolic Disease

AR 231453 is a potent, specific and orally available GPR119 agonist. AR 231453 can stimulate β-cell replication and improve islet graft function s.

HY-B1416A

Efaroxan hydrochloride	Adrenergic Receptor Imidazoline Receptor	Metabolic Disease Cardiovascular Disease
Efaroxan hydrochloride is a potent, selective and orally active α2-adrenoceptor antagonist, with antidiabetic activity. Efaroxan hydrochloride is a selective I1-Imidazoline receptor antagonist. Efaroxan hydrochloride can be used for the research of cardiovascular disease.

HY-P5161A

FC382K10W15 TFA
GCGR Metabolic Disease

FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research.

HY-121515

DPM-1001	Phosphatase	Metabolic Disease
DPM-1001 is a potent, specific, orally active and non-competitive inhibitor of protein-tyrosine phosphatase (PTP1B) with an IC₅₀ of 100 nM. DPM-1001 is an analog of the specific PTP1B inhibitor MSI-1436. DPM-1001 has anti-diabetic property.

HY-15656S

Ceritinib D7 LDK378 d₇	Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R	Cancer Endocrinology
Ceritinib-d₇ is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

HY-15697

TUG-770	Free Fatty Acid Receptor	Metabolic Disease
TUG-770 is a potent, selective and orally active GPR40/FFA1 agonist with an EC₅₀ of 6 nM for human FFA1. TUG-770 shows a high selectivity for FFA1 over FFA2, FFA3, FFA4, PPARγ, other receptors, transporters, and enzymes. TUG-770 can be uesd for type 2 diabetes research.

HY-12699

RO5166017	Trace Amine-associated Receptor (TAAR)	Metabolic Disease
RO5166017 is an orally active and species-crosses TAAR1 agonist, with K_i values of 1.9 nM, 2.7 nM, 31 nM and 24 nM for mouse, rat, human and cynomolgus monkey, respectively.

HY-P2541A

GIP (1-30) amide, porcine TFA	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42). GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-114299

Salcaprozate sodium SNAC	Others	Others
Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation.

HY-114456

Ganglioside GM3	Others	Metabolic Disease
Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia.

HY-13232

ITK antagonist	Itk	Inflammation/Immunology
ITK antagonist (compound 10 n) is a potent, orally active and selective ITK (Interleukin-2 inducible T-cell kinase) antagonist (IC₅₀=1 and 20 nM in different assays). ITK antagonist inhibits insulin receptor kinase (IRK) with an IC₅₀ of 160 nM.

HY-P1226

HAEGTFTSD	GCGR	Metabolic Disease
HAEGTFTSD is a 9-residue peptide of human GLP-1 peptide or GLP-1(7-36), amide (HY-P0054A). GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretionin a glucose-dependant manner

HY-N0479

Licarin B (-)-Licarin B	PPAR GLUT	Metabolic Disease
Licarin B, a nitric oxide production inhibitor extracted from the component of the seeds of Myristica fragrans, improves insulin sensitivity via PPARγ and activation of GLUT4 in the IRS-1/PI3K/AKT pathway.

HY-153485

Cimdelirsen ISIS 766720; IONIS-GHR-LRx	Small Interfering RNA (siRNA)	Others
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.

HY-P2450

Leucinostatin A Antibiotic P168	Fungal Antibiotic	Cancer Infection
Leucinostatin A (Antibiotic P168) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans. Leucinostatin A is a hydrophobic nonapeptide antibiotic. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells. Antiprotozoal activies.

HY-N9410S

Lysophosphatidylcholine 18:2-d9 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC-d₉	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Lysophosphatidylcholine 18:2-d₉ is deuterium labeled Lysophosphatidylcholine 18:2. Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary

HY-P99218

Robatumumab Sch 717454; 19D12	IGF-1R	Cancer
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research.

HY-W009204S5

Fmoc-Ala-OH-13C3	Isotope-Labeled Compounds PPAR	Metabolic Disease
Fmoc-Ala-OH-¹³C₃ is a ¹³C-labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-ind

HY-153485A

Cimdelirsen sodium ISIS 766720 sodium; IONIS-GHR-LRx sodium	Small Interfering RNA (siRNA)	Others
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.

HY-13594

Chlorin e6	Parasite	Cancer Infection
Chlorin e6 is a photosensitizer. Chlorin e6 has significantly high photosensitizing activity when present in insulin-containing conjugates and thus able to be internalized by receptor-expressing cells. Chlorin E6 effects viability and mitochondrial activity of Leishmania major and Leishmania braziliensis promastigotes.

HY-12185

BRD7389	Ribosomal S6 Kinase (RSK)	Cancer Metabolic Disease
BRD7389 is a specific RSK family kinase inhibitor with IC₅₀s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively. BRD7389 is a small-molecule inducer of insulin expression in pancreatic α-cells.

HY-124771

RH01386	Apoptosis	Metabolic Disease
RH01386 is a small molecule that can prevent endoplasmic reticulum stress (ERS)-induced β cell dysfunction and death, and inhibits proapoptotic gene expression. RH01386 restores ERS-impaired glucose-stimulated insulin secretion responses. RH01386 has the potential for type 2 diabetes treatment.

HY-101064S1

Fmoc-leucine-13C6,15N	PPAR	Metabolic Disease
Fmoc-leucine-¹³C₆,¹⁵N is a ¹⁵N-labeled and ¹³C-labled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity

HY-114196

Aclimostat ZGN-1061	Others	Metabolic Disease
Aclimostat (ZGN-1061) is a potent inhibitor of the MetAP2 enzyme and displays favorable efficacy and safety in preclinical studies. ZGN-1061 produced similar efficacy as beloranib for weight loss, improvements in metabolic parameters in a mouse model of obesity and insulin resistance, and concordant changes in gene transcription in HepG2 cells.

HY-101064

Fmoc-leucine N-FMOC-leucine; NPC 15199; NSC 334290	PPAR	Metabolic Disease
Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity.

HY-P1072

PHM-27 (human)	CGRP Receptor	Metabolic Disease Cardiovascular Disease
PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC₅₀ of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism.

HY-P4790

Acetyl-Exenatide	PI3K Akt	Metabolic Disease
Acetyl-Exenatideyes is an acetylated derivative of Exenatide. Exenatide has the function similar to insulin, which can be used for research of type 2 diabetes. Exenatide can promote Th17 differentiation, inhibits Tregs differentiation, downregulates PI3K/Akt/FoxO1 phosphorylation.

HY-12402

SBC-115076	Ser/Thr Protease	Cardiovascular Disease
SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism.

HY-125798

2,3-Dehydro-2-deoxy-N-acetylneuraminic acid Neu5Ac2en; DANA	Influenza Virus	Infection
N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid (Neu5Ac2en) is a potent neuraminidase (sialidase) inhibitor. N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid shows inhibitory activities against human neuraminidase enzymes with IC₅₀s of 143, 43, 61, and 74 μM for NEU1, NEU2, NEU3, and NEU4, respectively. Anti-influenza virus activity.

HY-105285

Piromelatine Neu-P11	Melatonin Receptor 5-HT Receptor P2X Receptor TRP Channel Sodium Channel	Neurological Disease
Piromelatine (Neu-P11) is a melatonin MT₁/MT₂ receptor agonist, serotonin 5-HT_1A/5-HT_1D agonist, and serotonin 5-HT_2B antagonist. Piromelatine (Neu-P11) possesses sleep promoting, analgesic, anti-neurodegenerative, anxiolytic and antidepressant potentials. Piromelatine (Neu-P11) also possesses pain-related P2X3, TRPV1, and Nav1.7 channel-inhibition capacities.

HY-12717

Phentolamine	Adrenergic Receptor	Endocrinology
Phentolamine is a potent, selective and orally active α1 adrenergic and α2 adrenergic receptor antagonist. Phentolamine can be used for the research of erectile dysfunction.

HY-135337

Ethyl tosylcarbamate	Potassium Channel	Metabolic Disease
Ethyl tosylcarbamate is an intermediate in the synthesis of Gliclazide (G409877). Gliclazide is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC₅₀ of 184 nM.

HY-107725

BIBO3304 TFA	Neuropeptide Y Receptor	Metabolic Disease
BIBO3304 TFA is a potent, orally active, and selective neuropeptide Y (NPY) Y1 receptor antagonist, with subnanomolar affinity for both the human and the rat Y1 receptor (IC₅₀=0.38 and 0.72 nM, respectively).

HY-119152

CMX-2043	Insulin Receptor Tyrosinase Akt	Others
CMX-2043 is a novel analogue of α-Lipoic Acid (HY-N0492). CMX-2043 is effective in antioxidant effect, activation of insulin receptor kinase, soluble tyrosine kinase, and Akt phosphorylation. CMX-2043 shows protection against ischemia-reperfusion injury (IRI) in rat model.

HY-145110

IGF-1R inhibitor-2	IGF-1R	Cancer
IGF-1R inhibitor-2 (example 121) is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor. Downregulation of IGF-1R can reverse the transformed phenotype of tumor cells and potentially render them susceptible to apoptosis.

HY-P2501

Amylin (8-37), human	Amylin Receptor	Metabolic Disease
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus.

HY-P2802

α-Glucosidase α-D-Glucosidase	Glucosidase	Metabolic Disease
α-Glucosidase (α-D-Glucosidase), a carbohydrate hydrolyzing enzyme, catalyzes the liberation of α-glucose from the non-reducing end of the substrate. α-Glucosidase can facilitate the absorption of glucose by the small intestine. Inhibition of α-Glucosidase is an effective management of non-insulin-dependent diabetes mellitus (NIDDM).

HY-13203

NVP-TAE 226 TAE226	FAK Pyk2 IGF-1R Insulin Receptor Apoptosis	Cancer Endocrinology
NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC₅₀s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC₅₀s of 3.5 nM and 44 nM, respectively.

HY-131334

AMPK activator 4	AMPK	Metabolic Disease
AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect.

HY-121212

Icosabutate	Others	Metabolic Disease Inflammation/Immunology
Icosabutate, an orally active ω-3 polyunsaturated fatty acid, is an aeicosapentaenoic acid (EPA) derivative. Icosabutate overcomes the drawbacks of unmodified EPA for liver targeting and improves insulin sensitivity, hepatic inflammation and fibrosis. Icosabutate is well tolerated, and efficacious in lowering non-high-density lipoprotein cholesterol (non-HDL-C) levels in persistent hypertriglyceridemia .

HY-123797

KGA-2727	SGLT	Metabolic Disease
KGA-2727 is a first selective, high-affinity and orally active SGLT1 inhibitor with K_is of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (K_i for SGLT2/K_i for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 has antidiabetic efficacy.

HY-N11324

Bitis Nasicornis Venom Rhinoceros Viper Venom	Others	Metabolic Disease
Bitis Nasicornis Venom (Rhinoceros Viper Venom) is a snake venom that can be obtained from Bitis Nasicornis. Bitis Nasicornis Venom has anticoagulant activity. Bitis Nasicornis Venom also has insulinotropic effect, and can be used for the research of diabetes. Bitis Nasicornis Venom can increase in intracellular Ca²⁺ concentration and hence a contraction of the the isolated aortic strip in rabbit.

HY-N4143

Cyanidin 3-arabinoside	Phosphatase	Metabolic Disease
Cyanidin 3-arabinoside is a selective and reversible protein tyrosine phosphatase 1B (PTP1B) inhibitor, with an IC₅₀ of 8.91 μM. Cyanidin 3-arabinoside is potential for the research of type 2 diabetes.

HY-19522

Seladelpar
MBX-8025
PPAR Metabolic Disease

Seladelpar (MBX-8025) is an orally active, potent (50% effect concentration EC₅₀ 2 nM), and specific PPAR-δ agonist.
HY-139409

2-Deoxy-D-glucose 6-phosphate
Others Metabolic Disease

2-Deoxy-D-glucose 6-phosphate is an intermediate of 2-deoxy-D-glucose (2-DG) . 2-Deoxy-D-glucose is incorporated into glycogen.

HY-101906

DC260126	Free Fatty Acid Receptor Apoptosis	Metabolic Disease
DC260126 is a potent antagonist of GPR40 (FFAR1). DC260126 dose-dependently inhibits GPR40-mediated Ca²⁺ elevations stimulated by linoleic acid, oleic acid, palmitoleic acid and lauric acid (IC₅₀: 6.28, 5.96, 7.07, 4.58 μM, respectively). DC260126 could protect MIN6 β cells from palmitate-induced ER stress and apoptosis.

HY-101064S3

Fmoc-leucine-d10	PPAR
Fmoc-leucine-d₁₀ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1].

HY-145935

NT219	Insulin Receptor STAT	Cancer
NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has the potential for the research of cancer diseases.

HY-110135A

NBI-31772 hydrate	IGF-1R	Neurological Disease
NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). NBI-31772 hydrate is also a nonpeptide ligand that releases bioactive IGF-I from the IGF-I/IGFBP-3 complex (K_is=1-24 nM for all six human subtypes). Anxiolytic and antidepressant-like effects.

HY-10252

NVP-ADW742 ADW742; GSK 552602A; ADW	IGF-1R Insulin Receptor Apoptosis	Cancer Endocrinology
NVP-ADW742 (ADW742) is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC₅₀ of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC₅₀ of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells.

HY-101064S2

Fmoc-leucine-d3 N-FMOC-leucine-d₃; NPC 15199-d₃; NSC 334290-d₃	PPAR
Fmoc-leucine-d₃ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1].

HY-P99294

Ganitumab AMG 479; Human Anti-IGF1R Recombinant Antibody	IGF-1R	Cancer
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the *human type 1 insulin-like growth factor receptor* (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (K_D=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer.

HY-P3608

[Des-His1,Glu9] Glucagon	GCGR	Metabolic Disease
[Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes.

HY-W011012

Adenosine 5'-monophosphate disodium	Adenosine Receptor	Metabolic Disease
Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes.

HY-15424

5-Iodotubercidin NSC 113939; 5-ITu	Adenosine Kinase	Cancer
5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC₅₀ of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin.

HY-14771A

Imeglimin hydrochloride EMD 387008 hydrochloride	Mitochondrial Metabolism Reactive Oxygen Species	Metabolic Disease
Imeglimin hydrochloride (EMD 387008) is an oral glucose-lowering agent. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function.

HY-14860A

1-Deoxynojirimycin hydrochloride Duvoglustat hydrochloride	Glucosidase PI3K Bacterial Antibiotic	Infection Metabolic Disease
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features.

HY-14860

1-Deoxynojirimycin Duvoglustat	Glucosidase PI3K	Metabolic Disease
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features.

HY-124557

Mahanimbine	Others	Metabolic Disease Inflammation/Immunology
Mahanimbine is an orally active alkaloid from Murraya koenigii. Mahanimbine inhibits progression of high-fat diet (HFD)-induced metabolic complications in mice.

HY-147705

PPARγ phosphorylation inhibitor 1	PPAR	Metabolic Disease
PPARγ phosphorylation inhibitor 1 (Compound 10) is a potent PPARγ binder with the IC₅₀ of 24 nM. PPARγ phosphorylation inhibitor 1 inhibits CDK5-mediated phosphorylation of PPARγ Ser273 with the IC₅₀ of 160 nM. PPARγ phosphorylation inhibitor 1 displays negligible PPARγ agonism in a reporter gene assay. Antidiabetic effects.

HY-19835

LY2922470	Free Fatty Acid Receptor	Metabolic Disease
LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40), with EC₅₀s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with significant increases in insulin and GLP-1, is potential for the treatment of type 2 diabetes mellitus (T2DM).

HY-137638

Sp-5,6-DCl-cBIMPS	PKA	Metabolic Disease
Sp-5,6-DCl-cBIMPS is a potent and specific cAMP-dependent protein kinases (cAMP-PK) activator. Sp-5,6-DCl-cBIMPS stimulates insulin release. Sp-5,6-DCl-cBIMPS inhibits U46619-induced activation of Rho, Gq and G12/G13 in platelets.

HY-P2090

Angiopeptin	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research.

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research.

HY-100560

Abscisic acid (S)-(+)-Abscisic acid; ABA	Endogenous Metabolite Proton Pump	Metabolic Disease
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H⁺-ATPase) and leads to the plasma membrane depolarization in a Ca²⁺-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome.

HY-P3622

(Ser8)-GLP-1 (7-36) amide, human	GCGR	Metabolic Disease
(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion.

HY-112584

JBSNF-000088 6-Methoxynicotinamide	Others	Metabolic Disease
JBSNF-000088 (6-Methoxynicotinamide), a analog of nicotinamide (NA), is a potent and orally active Nicotinamide N-methyltransferase (NNMT) inhibitor with IC₅₀s of 1.8 µM, 2.8 µM, and 5.0 µM for human NNMT, monkey NNMT and mouse NNMT, respectively. JBSNF-000088 inhibits NNMT activity, reduces MNA levels and drives insulin sensitization, glucose modulation and body weight reduction in animal models of metabolic disease.

HY-P1928

Humanin	Bcl-2 Family	Endocrinology Neurological Disease
Humanin, an anti-apoptotic peptide of 24 amino acids, is a Bax inhibitor. Humanin prevents the translocation of Bax from cytosol to mitochondria, blocks Bax from the inactive to active conformation. Humanin is a mitochondria-associated peptide with a neuroprotective effect against AD-related neurotoxicity. Humanin also improves overall insulin sensitivity in animal. Humanin are related to aging. Humanin analogue, in which the serine at position 14 is replaced by glycine, names HNG.

HY-18555

TMPA	AMPK	Cancer Metabolic Disease Inflammation/Immunology
TMPA is a high-affinity Nur77 antagonist that binds to Nur77 leading to the release and shuttling of LKB1 in the cytoplasm to activate AMPKα. TMPA effectively lowers blood glucose and attenuates insulin resistance in type II db/db, high-fat diet and streptozotocin-induced diabetic mice. TMPA reduces RICD (restimulation-induced cell death) in human T cells, can also be used in studies of cancer and T-cell apoptosis dysregulation.

HY-107597

SU3327	JNK	Metabolic Disease Inflammation/Immunology
SU3327 is a potent, selective and substrate-competitive JNK inhibitor with an IC₅₀ of 0.7 μM. SU3327 also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC₅₀ of 239 nM. SU3327 shows less active against p38α and Akt kinase.

HY-135425

10,12-Tricosadiynoic acid	Acyltransferase	Metabolic Disease
10,12-Tricosadiynoic acid is a highly specific, selective, high affinity and orally active acyl-CoA oxidase-1 (ACOX1) inhibitor. 10,12-Tricosadiynoic acid can treat high fat diet- or obesity-induced metabolic diseases by improving mitochondrial lipid and ROS metabolism.

HY-103261

SCH28080	Proton Pump	Endocrinology
SCH28080 is a reversible, K⁺-competitive inhibitor of the gastric H,K-ATPase, with a K_i of 0.12 μM. SCH28080 is an effective inhibitor of acid secretion in vivo and with anti-gastric ulcer activity.

HY-125102

AZ12253801	IGF-1R	Cancer
AZ12253801 is an ATP-competitive IGF-1R tyrosine kinase inhibitor that shows ∼10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R–driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC₅₀ of 17 nmol/L. The IC₅₀ for epidermal growth factor receptor (EGFR)–driven proliferation is 440 nmol/L. Anti-tumor activity.

HY-139058

23-epi-26-Deoxyactein
27-Deoxyactein
PPAR Cancer Metabolic Disease

23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.

HY-120801

APX-115 Ewha-18278	NADPH Oxidase	Metabolic Disease Inflammation/Immunology
APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with K_i values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 effectively prevents kidney injury.

HY-10285A

Saxagliptin hydrate BMS-477118 hydrate	Dipeptidyl Peptidase	Metabolic Disease
Saxagliptin hydrate (BMS-477118 hydrate) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin hydrate has the peotential for type 2 diabetes mellitus research.

HY-10285

Saxagliptin BMS-477118	Dipeptidyl Peptidase	Metabolic Disease
Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research.

HY-120801A

APX-115 free base Ewha-18278 free base; Isuzinaxib free base	NADPH Oxidase	Endocrinology Inflammation/Immunology
APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with K_i values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base effectively prevents kidney injury.

HY-16448

Saxagliptin hydrochloride BMS-477118 hydrochloride	Dipeptidyl Peptidase	Metabolic Disease
Saxagliptin hydrochloride (BMS-477118 hydrochloride) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin hydrochloride has the peotential for type 2 diabetes mellitus research.

HY-N0755

Rhoifolin	Insulin Receptor GLUT NF-κB p38 MAPK Autophagy	Metabolic Disease Endocrinology Cancer
Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines.

HY-N7676

Marein	AMPK HDAC	Metabolic Disease Neurological Disease Cardiovascular Disease
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC₅₀ of 100 µM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects.

HY-117427

D5D-IN-326	Others	Metabolic Disease
D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC₅₀s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice.

HY-135680

I-OMe-Tyrphostin AG 538 I-OMe-AG 538	IGF-1R	Cancer Metabolic Disease
I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells. I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), with an IC₅₀ of 1 µM.

HY-12462

WS3	Others	Inflammation/Immunology
WS3 is a novel proliferative molecule that promotes pancreatic β cell proliferation in rodent and human primary islets. WS3 can be used for the research of type 1 diabetes.

HY-N0322

Cholesterol	Liposome Estrogen Receptor/ERR Endogenous Metabolite Bacterial	Metabolic Disease Cancer
Cholesterol is the major sterol in mammals. It is making up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist.

HY-P3579

Gastric Inhibitory Peptide, porcine	Insulin Receptor	Endocrinology
Gastric Inhibitory Peptide, porcine is a glucose-dependent insulinotropic polypeptide, is a 42 amino acid intestinal hormone with effects on fat and glucose metabolism.

HY-136065

bpV(phen)	PTEN Phosphatase Parasite Apoptosis	Cancer Infection Metabolic Disease Inflammation/Immunology
bpV(phen), a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC₅₀s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity.

HY-122818

bpV(phen) trihydrate	PTEN Phosphatase Parasite Apoptosis	Cancer Infection Metabolic Disease Inflammation/Immunology
bpV(phen) trihydrate, a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC₅₀s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) trihydrate inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) trihydrate strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) trihydrate can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity.

HY-14229

TGR5 Receptor Agonist CCDC	G protein-coupled Bile Acid Receptor 1 Calcium Channel	Metabolic Disease
TGR5 Receptor Agonist (CCDC), a potent Takeda G protein-coupled receptor 5 (TGR5; GPCR19) agonist, shows improved potency in the U2-OS cells and melanophore cells with pEC₅₀s of 6.8 and 7.5, respectively. TGR5 Receptor Agonist can induce peripheral and central hypersensitivity to bladder distension in mice, and increase intracellular Ca²⁺ concentration. TGR5 Receptor Agonist can also reduces food intake and improves insulin responsiveness, in diet-induced obese mice. TGR5 Receptor Agonist can be used to research diabetes, bladder hypersensitivity and anti-obesity.

HY-Y1750A

β-Aminopropionitrile hydrochloride BAPN hydrochloride	Monoamine Oxidase Endogenous Metabolite	Cancer Metabolic Disease
β-Aminopropionitrile (BAPN) hydrochloride is a specific, irreversible and orally active lysyl oxidase (LOX) inhibitor. β-Aminopropionitrile hydrochloride targets the active site of LOX or LOXL isoenzymes.

HY-Y1750

β-Aminopropionitrile BAPN	Monoamine Oxidase Endogenous Metabolite	Cancer Metabolic Disease
β-Aminopropionitrile (BAPN) is a specific, irreversible and orally active lysyl oxidase (LOX) inhibitor. β-Aminopropionitrile targets the active site of LOX or LOXL isoenzymes.

HY-N2515

Ginsenoside Rk1	NF-κB PI3K JAK Apoptosis	Cancer Inflammation/Immunology
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB. Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis. Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway.

HY-14393

Emodin Frangula emodin	SARS-CoV Casein Kinase Autophagy 11β-HSD	Cancer
Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects. Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice.

HY-N7426

3-Deoxyglucosone 3-Deoxy-D-glucosone	GLP Receptor	Metabolic Disease
3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes.

HY-P1944A

Apelin-13 TFA	Apelin Receptor (APJ)	Metabolic Disease Cardiovascular Disease
Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC₅₀ value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome.

HY-149254

PTP1B/AKR1B1-IN-1	Phosphatase Aldose Reductase	Metabolic Disease
PTP1B/AKR1B1-IN-1 is a dual inhibitor of protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), with IC₅₀s of 0.06 μM and 4.3 μM, respectively. PTP1B/AKR1B1-IN-1 also inhibits TC-PTP with an IC₅₀ value of 9 μM. PTP1B/AKR1B1-IN-1 serves as an insulin-mimetic agent in murine myoblasts, and reduces AKR1B1-dependent sorbitol accumulation. PTP1B/AKR1B1-IN-1 inhibits development of type 2 diabetes mellitus (T2DM) to control blood glucose levels.

HY-P1944

Apelin-13	Apelin Receptor (APJ)	Metabolic Disease Cardiovascular Disease
Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC₅₀ value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome.

Cat. No.	Product Name

HY-L016

Protein Tyrosine Kinase Compound Library

914 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 914 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L040

Anti-diabetic Compound Library

648 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 648 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

HY-L101

Anti-Liver Cancer Compound Library

1596 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 1596 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-W337897

Tetradecyl-β-D-maltoside	Biochemical Assay Reagents
Tetradecyl-β-D-maltoside is an absorption enhancer which can increase the nasal absorption of regular human insulin or the fast acting insulin analog lyspro-insulin.

HY-Y1892

Gelucire 44/14	Co-solvents
Gelucire 44/14 is a potential and safe absorption enhancer for improving the absorption of poorly absorbable agents including insulin and calcitonin by pulmonary delivery.

HY-P2802

α-Glucosidase α-D-Glucosidase	Enzyme
α-Glucosidase (α-D-Glucosidase), a carbohydrate hydrolyzing enzyme, catalyzes the liberation of α-glucose from the non-reducing end of the substrate. α-Glucosidase can facilitate the absorption of glucose by the small intestine. Inhibition of α-Glucosidase is an effective management of non-insulin-dependent diabetes mellitus (NIDDM).

HY-W011012

Adenosine 5'-monophosphate disodium

Biochemical Assay Reagents

Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes.

Cat. No.	Product Name	Target	Research Area

HY-P4062

Insulin peglispro BIL	Insulin Receptor	Metabolic Disease
Insulin peglispro (BIL) is a basal insulin with a flat, prolonged activity profile. Insulin peglispro can exhibit better glycaemic control compared to conventional insulins.

HY-108719

Insulin glargine
Insulin Receptor Metabolic Disease

Insulin glargine is a long-acting insulin analog. Insulin glargine can be used for the diabetes mellitus.
HY-P4070

Insulin icodec
Peptides Metabolic Disease

Insulin icodec is a basal insulin analog. Insulin icodec can be used for the research of type 2 diabetes.

HY-108743

Insulin degludec	Insulin Receptor	Endocrinology
Insulin degludec is an ultra-long-acting form of *insulin* used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC₅₀ value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.

HY-109556

Insulin Detemir	Akt ERK	Metabolic Disease
Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research.

HY-P1156

Insulin(cattle) insulin from bovine pancreas	Insulin Receptor	Metabolic Disease Endocrinology
Insulin cattle (Insulin from bovine pancreas) is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.

HY-108767

Insulin aspart B28Asp; B28-Asp-insulin; INA-X 14; insulin X 14	Insulin Receptor	Metabolic Disease
Insulin aspart (B28Asp) is a fast-acting analog of human insulin. Insulin aspart provides more rapid absorption than regular human insulin after subcutaneous administration. Insulin aspart can be used for researching diabetes.

HY-109555

Insulin glulisine HMR 1964	Insulin Receptor	Metabolic Disease
Insulin glulisine (HMR 1964) is a rapid-acting insulin analogue, it mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin. Insulin glulisine can be used for the research of diabetes.

HY-P0035

Insulin (human)
Insulin Receptor Metabolic Disease Endocrinology

Insulin (human) is a polypeptide hormone that regulates the level of glucose.

HY-P1901

Insulin alpha-chain (1-13)	Peptides	Metabolic Disease
Insulin alpha-chain (1-13) is a human leucocyte antigen (HLA)-DR4-restricted epitope comprising the first 13 amino acids of the insulin A-chain.

HY-P2511

Insulin β Chain Peptide (15-23)	Peptides	Metabolic Disease
Insulin β Chain Peptide (15-23), also known as INS, is an insulin-derived peptide recognized by islet-associated T cells. The Insulin β Chain Peptide (15-23) tetramer stained the INS-reactive CTL clone G9C8, but neither this tetramer nor the negative control tetramer (TUM) stained the splenic CD8+ T cells from NOD or 8.3-TCRαβtransgenic NOD mice.

HY-P4061

Insulin-like growth factor II IGF-II; IGF-2	IGF-1R	Metabolic Disease Neurological Disease
Insulin-like growth factor II (IGF-2) is the principal somatomedin of human serum. Insulin-like growth factor II exerts permissive and direct effects on neurite outgrowth and enhances survival of sympathetic and sensory neurons.

HY-P1745

InsB (9-23) insulin B chain (9-23)	Peptides	Inflammation/Immunology
InsB (9-23) is an insulin B-chain peptide that binds to a class II histocompatibility complex (MHC) allele called I-Ag7. InsB (9-23) can be used to treat a number of autoimmune related diseases like Type 1 diabetes.

HY-P1773

IGF-I (30-41) insulin-like Growth Factor I (30-41)	Peptides	Metabolic Disease Inflammation/Immunology
IGF-I (30-41) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).

HY-P1773A

IGF-I (30-41) (TFA) insulin-like Growth Factor I (30-41) (TFA)	IGF-1R	Metabolic Disease Inflammation/Immunology
IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).

HY-P1777

IGF-I (24-41) insulin-like Growth Factor I (24-41)	IGF-1R	Metabolic Disease Inflammation/Immunology
IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) is amino acids 24 to 41 fragment of IGF-I. IGF-I, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I is partly responsible for systemic growth hormone (GH) activities. IGF-I has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) regulates somatic growth and behavioral development.

HY-P1777A

IGF-I (24-41) (TFA) insulin-like Growth Factor I (24-41) (TFA)	IGF-1R	Metabolic Disease Inflammation/Immunology
IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) TFA is amino acids 24 to 41 fragment of IGF-I. IGF-I TFA, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I TFA is partly responsible for systemic growth hormone (GH) activities. IGF-I TFA has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) TFA regulates somatic growth and behavioral development.

HY-P1776

*[pTyr1146][pTyr1150][pTyr1151]Insulin* Receptor (1142-1153)**	Insulin Receptor	Metabolic Disease
[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates.

HY-P2534

C-Peptide 2, rat
Peptides Metabolic Disease

C-Peptide 2, rat, 31-amino-acid peptide, is a component of proinsulin. C-Peptide 2, rat can inhibit glucose-induced insulin secretion.
HY-35028

Boc-Glu-Ofm
Amino Acid Derivatives Others

Boc-Glu-Ofm is a peptide. Boc-Glu-Ofm has been used for the synthesis of ester insulin and cyclic peptide mixtures.

HY-P4685

(Sar1,Ile4,8)-Angiotensin II	Angiotensin Receptor	Metabolic Disease
(Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β.

HY-P3616

Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide	GCGR	Metabolic Disease
Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide is a biotin labeled glucagon-like peptide-1-(7-36). Glucagon-like peptide-1-(7-36) is a gastrointestinal peptide with antidiabetogenic activity, and can increase the release of insulin.

HY-P3255

DA-JC4	Insulin Receptor	Inflammation/Immunology Neurological Disease
DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways.

HY-P1257

Xenin-8	Peptides	Metabolic Disease
Xenin-8, a C-terminal octapeptide, is a biologically active fragment of Xenin. Xenin is a 25-amino acid peptide of the neurotensin/xenopsin family. Xenin-8 stimulates basal insulin secretion and potentiates the insulin response to glucose in a dose-dependent manner (EC₅₀=0.16 nM).

HY-P3863

Pancreastatin (swine)	Peptides	Inflammation/Immunology
Pancreastatin (swine) is a 49-residue peptide which strongly inhibits glucose-induced insulin release. Pancreastatin (swine) can be isolated and characterized from porcine pancreas.

HY-P1257A

Xenin-8 TFA	Peptides	Metabolic Disease
Xenin-8 TFA, a C-terminal octapeptide, is a biologically active fragment of Xenin. Xenin is a 25-amino acid peptide of the neurotensin/xenopsin family. Xenin-8 TFA stimulates basal insulin secretion and potentiates the insulin response to glucose in a dose-dependent manner (EC₅₀=0.16 nM).

HY-P3577

[Tyr0] Gastric Inhibitory Peptide (23-42), human	Insulin Receptor	Metabolic Disease
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research.

HY-P3580

Acetyl Gastric Inhibitory Peptide (human) Human N-acetyl GIP	Insulin Receptor	Endocrinology Metabolic Disease
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity.

HY-P3848

Tyr0-Neurokinin A	Peptides	Metabolic Disease Neurological Disease
Tyr0-Neurokinin A is a neuropeptide belongs to tachykinin peptide family. Tyr0-Neurokinin A is an agonist of Tacr2. Tyr0-Neurokinin A can be used in the research of insulin resistance, obesity, diabetes.

HY-P0276

GIP, human Gastric Inhibitory Peptide (GIP), human	Insulin Receptor	Metabolic Disease
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion.

HY-P0276A

GIP, human TFA Gastric Inhibitory Peptide (GIP), human TFA	Insulin Receptor	Metabolic Disease
GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of *glucose-dependent insulin* secretion** and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion.

HY-P1871A

Amylin (IAPP), feline TFA	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion.

HY-P3578

Gastric Inhibitory Polypeptide (1-30), porcine	Insulin Receptor	Endocrinology
Gastric Inhibitory Polypeptide (1-30), porcine lacks the C-terminal 12 amino acid residues of natural gastric inhibitory polypeptide (GIP), exhibits biologic activity by potentiating the release of insulin and somatostatin.

HY-P1871

Amylin (IAPP), feline	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion.

HY-P1184

HNGF6A	Reactive Oxygen Species	Metabolic Disease Neurological Disease Cardiovascular Disease
HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo.

HY-117483

Gly-Pro-Glu	Peptides	Neurological Disease
Gly-Pro-Glu is a neuroactive peptide with a potent action on acetylcholine release. Gly-Pro-Glu is the N-terminal tripeptide of insulin-like growth factor-I. Gly-Pro-Glu inhibits glutamate binds to N-methyl-D-aspartate (NMDA) receptor with an IC₅₀ value of 14.7 μM. Gly-Pro-Glu can be used for the research of neuroprotection .

HY-P1184A

HNGF6A TFA	Reactive Oxygen Species	Metabolic Disease Neurological Disease Cardiovascular Disease
HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo.

HY-P0262

Galantide	Neuropeptide Y Receptor	Metabolic Disease Inflammation/Immunology Neurological Disease Endocrinology
Galantide, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (K_D<0.1 nM and ~6 nM) in the rat hypothalamus. Galantide dose dependently (IC₅₀=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide appears to bind to a single population of SP receptors (K_D~40 nM).

HY-P3019

Urocortin III (human)	CRFR	Endocrinology Neurological Disease Cardiovascular Disease
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) selectively binds to type 2 CRF receptors with K_i values of 13.5, 21.7, and >100 nM for mCRF2β, rCRF2α, and hCRF1, respectively. Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion.

HY-P2048A

MOTS-c(human) acetate	AMPK GLUT	Metabolic Disease
MOTS-c(human) acetate is a mitochondrial-derived peptide. MOTS-c(human) acetate induces the accumulation of AMP analog AICAR, increases activation of AMPK and expression of its downstream GLUT4. MOTS-c(human) acetate induces glucose uptake and improves insulin sensitivity. MOTS-c(human) acetate has implications in the regulation of obesity, diabetes, exercise, and longevity.

HY-W037817

Dimethyl L-glutamate Dimethyl glutamate	Potassium Channel Bacterial	Infection Metabolic Disease
Dimethyl L-glutamate (Dimethyl glutamate), a membrane-permeable analog of Glutamate, can stimulate *insulin* release induced by Glucose. Dimethyl L-glutamate suppresses the K_ATP channel activities. Dimethyl L-glutamate inhibits E. gracilis growth and causes abnormal cell division. Dimethyl L-glutamate can be used in the research of diabetes, glucose transport, phosphorylation, and further metabolism.

HY-P3542

Des His1, Glu8 Exendin-4	GCGR	Metabolic Disease
Des His1, Glu8 Exendin-4 is a potent glucagon-like peptide-1 receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal.

HY-P0150

Glucagon (19-29), human
GCGR Neurological Disease

Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.

HY-P2093

S961	Insulin Receptor	Metabolic Disease
S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC₅₀s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.

HY-P2093B

S961 acetate	Insulin Receptor	Metabolic Disease
S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC₅₀s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.

HY-P2093A

S961 TFA	Insulin Receptor	Metabolic Disease
S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC₅₀s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.

HY-P0054A

GLP-1(7-36), amide Glucagon-like peptide-1 (GLP-1)(7-36), amide; Human GLP-1 (7-36), amide	GCGR	Metabolic Disease
GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretion.

HY-P1475

C-Peptide, dog
C-Peptide (dog)
Peptides Metabolic Disease

C-Peptide, dog is a component of proinsulin, released from pancreatic beta cells into blood together with insulin.
HY-P0055

GLP-1(7-37)
GCGR Metabolic Disease

GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

HY-P2080B

GIP (1-30) amide,human acetate	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human acetate dose-dependently promotes insulin secretion over the range 10^-9-10^-6 M.

HY-P2080

GIP (1-30) amide,human	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human dose-dependently promotes insulin secretion over the range 10^-9-10^-6 M.

HY-17365

Octreotide acetate SMS 201-995 acetate	Somatostatin Receptor	Inflammation/Immunology Cardiovascular Disease Endocrinology Cancer
Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, glucagon, and *insulin* more potently.

HY-P0055A

GLP-1(7-37) acetate
GCGR Metabolic Disease

GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

HY-P3954

Somatostatin-28 (sheep)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion.

HY-P0054

GLP-1(7-36), amide acetate Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-P0054B

GLP-1(7-36), amide TFA Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-P2542

GIP (3-42), human	Insulin Receptor	Metabolic Disease
GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo.

HY-P1790

Axltide
JAK Metabolic Disease

Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases.

HY-P1742

Gluten Exorphin B5	Opioid Receptor	Metabolic Disease
Gluten Exorphin B5 is an exogenous opioid peptides derived from wheat gluten, acts on opioid receptor, increases postprandial plasma insulin level in rats.

HY-P3864

Pancreastatin (37-52), human	Peptides	Metabolic Disease
Pancreastatin (37-52), human is a pancreastatin fragment. Pancreastatin a CgA-derived peptide (CgA residues 250–301) with biological activity, inhibited the releasing of insulin by islet beta cells.

HY-P1980

A-71915 TFA	Apoptosis	Metabolic Disease
A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells.

HY-P1473

Amylin (8-37), rat Amylin (8-37) (mouse, rat)	Amylin Receptor	Metabolic Disease
Amylin (8-37), rat is a truncated analog of native Amylin that selectively inhibits insulin-related glucose uptake and glycogen deposition in muscle tissue. Amylin (8-37), rat is a weak amylin receptor (AMY) antagonist.

HY-P4860

Adropin (34-76) (human, mouse, rat)	Akt	Metabolic Disease
Adropin (34-76) (human, mouse, rat) regulates fuel selection preferences in skeletal muscle. Adropin increases insulin-induced Akt phosphorylation and cell-surface expression of GLUT4, in diet-induced obesity (DIO) mouse.

HY-P4785

Acetyl-Amylin (8-37) (human)
Amylin Receptor Metabolic Disease

Acetyl-Amylin (8-37) (human) is a specific amylin antagonist.

HY-P3865

Pancreastatin (33-49), porcine	Peptides	Metabolic Disease
Pancreastatin (33-49), porcine is a pancreastatin fragment. Pancreastatin is a peptide isolated from porcine pancreas which has insulin-suppressive actions in vitro. Pancreastatin (33-49), porcine enhances the priming effect of glucose.

HY-P1070

Amylin, amide, human DAP amide, human	Amylin Receptor	Metabolic Disease
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent.

HY-P3401

GHGVYGHGVYGHGPYGHGPYGHGLYW	Peptides	Others
GHGVYGHGVYGHGPYGHGPYGHGLYW (DgHBP-2) is 26-amino-acid-long consensus peptide derived from histidine-rich beak protein-2 (DgHBP-2). GHGVYGHGVYGHGPYGHGPYGHGLYW can be used fabricated glucose-responsive insulin delivery system.

HY-P1070A

Amylin, amide, human TFA DAP amide, human TFA	Amylin Receptor	Metabolic Disease
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent.

HY-108905

Mecasermin Human IGF-I; FK 780	IGF-1R	Metabolic Disease
Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies.

HY-P2541

GIP (1-30) amide, porcine	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42). GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P5161A

FC382K10W15 TFA
GCGR Metabolic Disease

FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research.

HY-P3866

[Asu1,6]-Oxytocin	Peptides	Metabolic Disease
[Asu1,6]-Oxytocin is an analog of oxytocin. [Asu1,6]-Oxytocin reverses insulin resistance and glucose intolerance prior to reduction of obesity. [Asu1,6]-Oxytocin has the potential for the research of obesity and diabetes.

HY-P2541A

GIP (1-30) amide, porcine TFA	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42). GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P4657

Human Growth Hormone (1-43)	Peptides	Endocrinology
Human Growth Hormone (1-43) is an N-terminal fragment of human growth hormone with specific and pronounced insulin-like activity. Human Growth Hormone (1-43) can be used to study the function and metabolic pathways of growth hormone, a potential obesity-related factor.

HY-P1226

HAEGTFTSD	GCGR	Metabolic Disease
HAEGTFTSD is a 9-residue peptide of human GLP-1 peptide or GLP-1(7-36), amide (HY-P0054A). GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretionin a glucose-dependant manner

HY-P3778

γ-Bag cell peptide	Peptides	Neurological Disease
γ-bag cell peptide is a peptide. γ-bag cell peptide is located near the N-terminus of the egg laying prohormone, the vesicle is released upon insulin stimulation. γ-bag cell peptide can be used for the research of the central and peripheral nervous systems.

HY-P1072

PHM-27 (human)	CGRP Receptor	Metabolic Disease Cardiovascular Disease
PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC₅₀ of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism.

HY-P4790

Acetyl-Exenatide	PI3K Akt	Metabolic Disease
Acetyl-Exenatideyes is an acetylated derivative of Exenatide. Exenatide has the function similar to insulin, which can be used for research of type 2 diabetes. Exenatide can promote Th17 differentiation, inhibits Tregs differentiation, downregulates PI3K/Akt/FoxO1 phosphorylation.

HY-119152

CMX-2043	Insulin Receptor Tyrosinase Akt	Others
CMX-2043 is a novel analogue of α-Lipoic Acid (HY-N0492). CMX-2043 is effective in antioxidant effect, activation of insulin receptor kinase, soluble tyrosine kinase, and Akt phosphorylation. CMX-2043 shows protection against ischemia-reperfusion injury (IRI) in rat model.

HY-P2501

Amylin (8-37), human	Amylin Receptor	Metabolic Disease
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus.

HY-P3608

[Des-His1,Glu9] Glucagon	GCGR	Metabolic Disease
[Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes.

HY-P2472

Orphan GPCR SP9155 agonist P550 (mouse, rat) 26RFa (mouse, rat)	Peptides	Metabolic Disease
Orphan GPCR SP9155 agonist P550 (mouse, rat) (26RFa (mouse, rat)), a member of the RFamide peptide family with orexigenic effect, is the cognate ligand of the mouse orphan receptor GPR103, also designated SP9155 or AQ27.

HY-P2090

Angiopeptin	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research.

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research.

HY-P3622

(Ser8)-GLP-1 (7-36) amide, human	GCGR	Metabolic Disease
(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion.

HY-P1928

Humanin	Bcl-2 Family	Endocrinology Neurological Disease
Humanin, an anti-apoptotic peptide of 24 amino acids, is a Bax inhibitor. Humanin prevents the translocation of Bax from cytosol to mitochondria, blocks Bax from the inactive to active conformation. Humanin is a mitochondria-associated peptide with a neuroprotective effect against AD-related neurotoxicity. Humanin also improves overall insulin sensitivity in animal. Humanin are related to aging. Humanin analogue, in which the serine at position 14 is replaced by glycine, names HNG.

HY-P3579

Gastric Inhibitory Peptide, porcine	Insulin Receptor	Endocrinology
Gastric Inhibitory Peptide, porcine is a glucose-dependent insulinotropic polypeptide, is a 42 amino acid intestinal hormone with effects on fat and glucose metabolism.

HY-P1944A

Apelin-13 TFA	Apelin Receptor (APJ)	Metabolic Disease Cardiovascular Disease
Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC₅₀ value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome.

HY-P1944

Apelin-13	Apelin Receptor (APJ)	Metabolic Disease Cardiovascular Disease
Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC₅₀ value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome.

Cat. No.	Product Name	Target	Research Area

HY-P99665

Insulin efsitora alfa LY-3209590	Insulin Receptor	Metabolic Disease
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes.

HY-P99530

Valanafusp alfa AGT-181; HIRMAb-IDUA	Insulin Receptor	Metabolic Disease
Valanafusp alfa (AGT-181) is a brain penetrating recombinant fusion protein of a chimeric monoclonal antibody against the human insulin receptor (HIR) and human iduronidase (IDUA). Valanafusp alfa can be used for the research of Mucopolysaccharidosis type I (MPS I) .

HY-P99197

Figitumumab CP-751871	IGF-1R	Cancer
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC₅₀ of 1.8 nM.

HY-P99218

Robatumumab Sch 717454; 19D12	IGF-1R	Cancer
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research.

HY-P99294

Ganitumab AMG 479; Human Anti-IGF1R Recombinant Antibody	IGF-1R	Cancer
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the *human type 1 insulin-like growth factor receptor* (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (K_D=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer.

Cat. No.	Product Name	Target	Category

HY-B0089

Acarbose BAY g 5421	Glucosidase	Saccharides Polysaccharides Structural Classification Microorganisms Source classification Metabolic Disease Disease Research Fields Anti-aging Classification of Application Fields
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC₅₀=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin.

HY-N1995

Methylswertianin	Others	Phenols Xanthones Polyphenols Structural Classification Swertia bimaculata (Sieb. et Zucc.) Hook. f. et Thoms. ex C. B. Clark Plants Source classification Gentianaceae Metabolic Disease Disease Research Fields Classification of Application Fields
Methylswertianin is an active constituent in Swertia punicea Hemsl, with anti-diabetic effect. Methylswertianin can abates type-2 diabetes, likely via the improvement of insulin resistance (IR).

HY-N3426

Kazinol B	NO Synthase Akt AMPK	Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants other families
Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of nitric oxide (NO) production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research.

HY-N9535

tert-OMe-byakangelicin	Others	Phenylpropanoids Coumarins Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Umbelliferae Angelica dahurica (Fisch. ex Hoffm.) Benth. et Hook. f. ex Franch. e
tert-OMe-byakangelicin is a coumarin that can enhances the adrenaline-induced lipolytic effect and inhibits insulin-stimulated triglyceride synthesis from glucose in fat cells.

HY-N9326

Uralenol	Phosphatase	Flavonoids Flavonols Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants other families
Uralenol is a natural PTP1B inhibitor (IC₅₀=21. 5 μM) from Broussonetia papyrifera. PTP1B have been shown to play a major role in the dephosphorylation of the insulin receptor in many cellular and biochemical studies.

HY-N8522

9,10-Dihydroxystearic acid	Others	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Euphorbiaceae Ricinus communis L.
9,10-Dihydroxystearic acid is an oxidation product of oleic acid. 9,10-Dihydroxystearic acid can improve glucose tolerance and insulin sensitivity in KKAy mice.

HY-W018499

(S)-2-Hydroxybutanoic acid	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Other Diseases Source classification Endogenous metabolite
(S)-2-Hydroxybutanoic acid is the S-enantiomer of 2-Hydroxybutanoic acid. 2-Hydroxybutanoic acid, a coproduct of protein metabolism, is an insulin resistance (IR) biomarker.

HY-N9410

Lysophosphatidylcholine 18:2 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC	Endogenous Metabolite	Natural Products Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Endogenous metabolite Disease markers Infection Endocrine diseases
Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment.

HY-N1419

Vaccarin	AMPK	Flavonoids Flavones Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants other families
Vaccarin is an active flavonoid glycoside associated with various biological functions. Vaccarin significantly promote wound healing and endothelial cells and fibroblasts proliferation in the wound site. Vaccarin ameliorates insulin resistance and steatosis by activating the AMPK signaling pathway.

HY-N1743

1-(4-Hydroxy-2-methoxyphenyl)-3-(4-hydroxy-3-prenylphenyl)	Phosphatase	Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Moraceae Broussonetia kazinoki Sieb. et Zucc.
1-(4-Hydroxy-2-methoxyphenyl)-3-(4-hydroxy-3-prenylphenyl), isolated from Broussonetia kazinoki, shows in vitro inhibition of protein tyrosine phosphatase 1B (PTP1B) with an IC₅₀ of 13.00 μM. PTP1B is a negative regulator of insulin action and an important mediator in the pathogenesis of insulinresistance and non-insulin dependent diabetes mellitus. PTP1B is regarded as a significant target for type 2 diabetes.

HY-N6181

Terrelumamide A	Others	Alkaloids Other Alkaloids Disease Research Fields Classification of Application Fields Endocrinology Source classification Microorganisms Marine natural products Marine microorganism
Terrelumamide A is a lumazine-containing peptide. Terrelumamide A is isolated from the culture broth of the marine-derived fungus Aspergillus terreus. Terrelumamide A exhibits pharmacological activity by improving insulin sensitivity. Terrelumamide A has the potential in the application of DNA sequence recognition.

HY-N9536

Cinnamtannin A2	GLP Receptor	Biflavones Phenols Flavanonols Polyphenols Structural Classification Flavonoids Lauraceae Plants Source classification Cinnamomum cassia Presl Metabolic Disease Disease Research Fields Classification of Application Fields
Cinnamtannin A2, a tetrameric procyanidin, can increases GLP-1 and insulin secretion in mice. Cinnamtannin A2 could upregulate the expression of corticotrophin releasing hormone. Cinnamtannin A2 exhibits antioxidant, anti-diabetic and nephroprotective effect.

HY-N10405

(R)-5-Hydroxy-1,7-diphenyl-3-heptanone	Keap1-Nrf2	Structural Classification Natural Products
(R)-5-Hydroxy-1,7-diphenyl-3-heptanone is a diarylheptanoid that can be found in Alpinia officinarum. (R)-5-Hydroxy-1,7-diphenyl-3-heptanone ameliorates oxidative stress and insulin resistance via activation of Nrf2/ARE pathway.

HY-135897

Urolithin C	Calcium Channel Reactive Oxygen Species Apoptosis Endogenous Metabolite	Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Endogenous metabolite
Urolithin C, a gut-microbial metabolite of Ellagic acid, is a glucose-dependent activator of insulin secretion. Urolithin C is a L-type Ca²⁺ channel opener and enhances Ca²⁺ influx. Urolithin C induces cell apoptosis through a mitochondria-mediated pathway and also stimulates reactive oxygen species (ROS) formation.

HY-N7073

Silymarin	SARS-CoV	Natural Products Classification of Application Fields Disease Research Fields Infection Inflammation/Immunology Neurological Disease Source classification Plants Compositae Glycine soya Cyamopsis tetragonoloba (L.) Taub.
Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 main protease (M^pro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research.

HY-B0089A

Acarbose sulfate Bay-g 5421 sulfate	Glucosidase	Saccharides Polysaccharides Structural Classification Microorganisms Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
Acarbose (BAY g 5421) sulfate, antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC₅₀=11 nM). Acarbose sulfate can potentiate the hypoglycemic effects of sulfonylureas or insulin.

HY-N0457

Chicoric acid Cichoric acid; Dicaffeoyltartaric acid	Reactive Oxygen Species Apoptosis	Phenylpropanoids Other Phenylpropanoids Phenols Polyphenols Classification of Application Fields Disease Research Fields Inflammation/Immunology Metabolic Disease Anti-aging Source classification Plants other families
Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects.

HY-B1021

Vincamine	Free Fatty Acid Receptor	Alkaloids Indole Alkaloids Classification of Application Fields Disease Research Fields Cardiovascular Disease Source classification Plants Apocynaceae Catharanthus roseus (L.) G. Don
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation. Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research.

HY-N3021

D-chiro-Inositol	Endogenous Metabolite	Structural Classification Natural Products Endogenous metabolite Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
D-chiro-Inositol is an epimer of myo-inositol found in certain mammalian glycosylphosphatidylinositol protein anchors and inositol phosphoglycans possessing insulin-like bioactivity. D-chiro-Inositol is used clinically for the treatment of polycystic ovary syndrome (PCOS) and diabetes mellitus, which can reduce hyperglycemia and ameliorate insulin resistance.

HY-W010031

1-Methyluric acid	Endogenous Metabolite	Natural Products Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Endogenous metabolite Disease markers Other disease
1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels.

HY-N0628

Kaempferitrin Lespedin; Lespenephryl	Insulin Receptor	Flavonoids Flavonols Phenols Polyphenols Classification of Application Fields Disease Research Fields Endocrinology Metabolic Disease Source classification Plants Leguminosae Bauhinia × blakeana Dunn
Kaempferitrin is a natural flavonoid, possesses antinociceptive, anti-inflammatory, anti-diabetic, antitumoral and chemopreventive effects, and activates *insulin* signaling pathway.

HY-15494

Picropodophyllin AXL1717; Picropodophyllotoxin; PPP	IGF-1R Apoptosis	Phenylpropanoids Structural Classification Lignans Plants Berberidaceae Source classification Dysosma versipellis (Hance) M. Cheng ex Ying Disease Research Fields Classification of Application Fields Endocrinology
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-N2209

Angeloylgomisin H	PPAR	Phenylpropanoids Lignans Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Schisandraceae Schisandra chinensis (Turcz.) Baill.
Angeloylgomisin H, as a major lignin extract of Schisandra rubriflora, has the potential to improve insulin-stimulated glucose uptake by activating PPAR-γ.

HY-N4244

Kakkalide	Reactive Oxygen Species	Isoflavones Monophenols Phenols Structural Classification Flavonoids other families Plants Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
Kakkalide is an isoflavone derived from the flowers of Pueraria lobata. Kakkalide ameliorates endothelial insulin resistance by suppressing reactive oxygen species (ROS)-associated inflammation.

HY-P1742

Gluten Exorphin B5	Opioid Receptor	Phenols Monophenols Natural Products Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Agrostidoideae Triticum aestivum L.
Gluten Exorphin B5 is an exogenous opioid peptides derived from wheat gluten, acts on opioid receptor, increases postprandial plasma insulin level in rats.

HY-N2118

Bilobetin	PPAR PKA	Biflavones Phenols Polyphenols Flavonoids Metabolic Disease Disease Research Fields Classification of Application Fields Source classification Plants Ginkgoaceae Ginkgo biloba
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity.

HY-128400

4'-Methoxychalcone	PARP	Flavonoids Chalcones Classification of Application Fields Disease Research Fields Cancer Source classification Plants Piperaceae Piper nigrum Linn.
4'-Methoxychalcone regulates adipocyte differentiation through PPARγ activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity.

HY-U00462

D-Mannoheptulose	Others	Saccharides Monosaccharides Metabolic Disease Disease Research Fields Classification of Application Fields Source classification Plants Lauraceae Persea americana Mill
D-Mannoheptulose is a major non-structural carbohydrate in avocado. D-mannoheptulose is a specific inhibitor of D-glucose phosphorylation. D-Mannoheptulose can block insulin release and utilization of carbohydrate in rat.

HY-N2421

Sequoyitol 5-O-Methyl-myo-inositol	Others	Natural Products Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Leguminosae Glycine max (L.) merr
Sequoyitol (5-O-Methyl-myo-inositol) is isolated from plants. Sequoyitol (5-O-Methyl-myo-inositol) decreases blood glucose, improves glucose intolerance, and is used to treat diabetes.

HY-N2177

3-Dehydrotrametenolic acid	Lactate Dehydrogenase Apoptosis	Triterpenes Terpenoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Polyporaceae Poria cocos
3-Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-Dehydrotrametenolic acid induces apoptosis and has anticancer activity.

HY-N0479

Licarin B (-)-Licarin B	PPAR GLUT	Phenylpropanoids Simple Phenylpropanols Metabolic Disease Disease Research Fields Classification of Application Fields Source classification Plants Myristicaceae Myristica fragrans Houtt.
Licarin B, a nitric oxide production inhibitor extracted from the component of the seeds of Myristica fragrans, improves insulin sensitivity via PPARγ and activation of GLUT4 in the IRS-1/PI3K/AKT pathway.

HY-P2450

Leucinostatin A Antibiotic P168	Fungal Antibiotic	Natural Products Classification of Application Fields Disease Research Fields Infection Source classification Microorganisms
Leucinostatin A (Antibiotic P168) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans. Leucinostatin A is a hydrophobic nonapeptide antibiotic. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells. Antiprotozoal activies.

HY-N11324

Bitis Nasicornis Venom Rhinoceros Viper Venom	Others	Snake Venoms Animals Animal Venoms
Bitis Nasicornis Venom (Rhinoceros Viper Venom) is a snake venom that can be obtained from Bitis Nasicornis. Bitis Nasicornis Venom has anticoagulant activity. Bitis Nasicornis Venom also has insulinotropic effect, and can be used for the research of diabetes. Bitis Nasicornis Venom can increase in intracellular Ca²⁺ concentration and hence a contraction of the the isolated aortic strip in rabbit.

HY-N4143

Cyanidin 3-arabinoside	Phosphatase	Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants other families
Cyanidin 3-arabinoside is a selective and reversible protein tyrosine phosphatase 1B (PTP1B) inhibitor, with an IC₅₀ of 8.91 μM. Cyanidin 3-arabinoside is potential for the research of type 2 diabetes.

HY-14860A

1-Deoxynojirimycin hydrochloride Duvoglustat hydrochloride	Glucosidase PI3K Bacterial Antibiotic	Saccharides Monosaccharides Metabolic Disease Disease Research Fields Classification of Application Fields Source classification Plants Commelinaceae Commelina communis
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features.

HY-14860

1-Deoxynojirimycin Duvoglustat	Glucosidase PI3K	Alkaloids Piperidine Alkaloids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Moraceae Morus alba Linn.
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features.

HY-124557

Mahanimbine	Others	Indole Alkaloids Alkaloids Structural Classification Rutaceae Plants Murraya koenigii (L.) Spreng Source classification Murraya exotica L. Mant. Inflammation/Immunology Disease Research Fields Classification of Application Fields
Mahanimbine is an orally active alkaloid from Murraya koenigii. Mahanimbine inhibits progression of high-fat diet (HFD)-induced metabolic complications in mice.

HY-100560

Abscisic acid (S)-(+)-Abscisic acid; ABA	Endogenous Metabolite Proton Pump	Sesquiterpenes Terpenoids Structural Classification Microorganisms other families Endogenous metabolite Plants Animals Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H⁺-ATPase) and leads to the plasma membrane depolarization in a Ca²⁺-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome.

HY-139058

23-epi-26-Deoxyactein 27-Deoxyactein	PPAR	Triterpenes Terpenoids Structural Classification other families Plants Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.

HY-N0755

Rhoifolin	Insulin Receptor GLUT NF-κB p38 MAPK Autophagy	Structural Classification Flavones Flavonoids Anacardiaceae Plants Rhus succedanea Disease Research Fields Cancer Classification of Application Fields Endocrinology
Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines.

HY-N7676

Marein	AMPK HDAC	Flavonoids Chalcones Phenols Polyphenols Classification of Application Fields Disease Research Fields Cardiovascular Disease Neurological Disease Source classification Plants other families
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC₅₀ of 100 µM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects.

HY-N0322

Cholesterol	Liposome Estrogen Receptor/ERR Endogenous Metabolite Bacterial	Steroids Structural Classification Endogenous metabolite Source classification Metabolic Disease Disease Research Fields Cancer Anti-aging Classification of Application Fields
Cholesterol is the major sterol in mammals. It is making up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist.

HY-Y1750

β-Aminopropionitrile BAPN	Monoamine Oxidase Endogenous Metabolite	Natural Products Classification of Application Fields Disease Research Fields Cancer Source classification Endogenous metabolite
β-Aminopropionitrile (BAPN) is a specific, irreversible and orally active lysyl oxidase (LOX) inhibitor. β-Aminopropionitrile targets the active site of LOX or LOXL isoenzymes.

HY-N2515

Ginsenoside Rk1	NF-κB PI3K JAK Apoptosis	Triterpenes Terpenoids Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Araliaceae Panax ginseng C. A. Meyer
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB. Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis. Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway.

HY-14393

Emodin Frangula emodin	SARS-CoV Casein Kinase Autophagy 11β-HSD	Quinones Anthraquinones Phenols Polyphenols Disease Research Fields Cancer Classification of Application Fields Source classification Plants Polygonaceae Rheum palmatum L.
Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects. Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice.

HY-N7426

3-Deoxyglucosone 3-Deoxy-D-glucosone	GLP Receptor	Saccharides Structural Classification Endogenous metabolite Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes.

Recombinant Proteins Recommended:

Insulin

Species:	Human (37) Rhesus Macaque (2) Mouse (14) Rat (1) Cynomolgus (2) Canine (2) Pig (1)
Tag:	His (42) SUMO (1) T7 (1) Tag Free (8) Avi (1) Myc (2) GST (4) Fc (8)
Source:	HEK293 (35) P. pastoris (7) Sf9 insect cells (4) E. coli (13)

Cat. No.	Product Name	Species	Source

HY-P73243

Insulin Protein, Human (P.pastoris)
insulin; INS; IDDM; ILPR; IRDN; MODY10
Human P. pastoris
HY-P73873

Insulin R/CD220 Protein, Human (HEK293, His)
CD 220; HHF5; INSR; insulin R; insulin receptor; IR
Human HEK293
HY-P73244

Insulin R/CD220 Protein, Human (sf9, His-GST)
CD 220; HHF5; INSR; insulin R; insulin receptor; IR
Human Sf9 insect cells
HY-P77515

Insulin R/CD220 Protein, Human (Biotinylated, HEK293, His)
CD 220; HHF5; INSR; insulin R; insulin receptor; IR
Human HEK293
HY-P70176

Insulin-like 3/INSL3 Protein, Human (HEK293, His)
rHuinsulin-like 3/INSL3, His; insulin-like 3; Leydig insulin-like peptide; Relaxin-like factor; INSL3; RLF; RLNL
Human HEK293
HY-P71805

Insulin-1/Ins1 Protein, Mouse (P.pastoris, Myc, His)
Ins1; Ins-1; insulin-1
Mouse P. pastoris
HY-P71805Y

Insulin-1/Ins1 Protein, Mouse (P.pastoris, Myc, His, solution)
Ins1; Ins-1; insulin-1
Mouse P. pastoris
HY-P70833

INSL4 Protein, Human (HEK293, His)
Early Placenta insulin-Like Peptide; EPIL; insulin-Like Peptide 4; Placentin; INSL4
Human HEK293
HY-P70291

Insulysin/IDE Protein, Human (HEK293, His)
rHuinsulin-degrading enzyme/IDE, His ; insulin-Degrading Enzyme; Abeta-Degrading Protease; insulin Protease; insulinase; Insulysin; IDE
Human HEK293
HY-P76455

INSL6 Protein, Human (HEK293, His)
insulin-like peptide INSL6; Relaxin/insulin-like factor 1; INSL6; RIF1
Human HEK293

HY-P700475

IGF2 Protein, Human (GST) insulin-like growth factor 2 (somatomedin A); INSIGF; pp9974; C11orf43; FLJ22066; FLJ44734; IGF2; insulin-like growth factor 2; IGF-II; somatomedin A; somatomedin-A; insulin-like growth factor II; insulin-like growth factor type 2; putative insulin-like growth factor II associated protein; chromosome 11 open reading frame 43; OTTHUMP00000011157; OTTHUMP00000011018	Human	E. coli

HY-P70698

IGF-I/IGF-1 Protein, Mouse (His) IGF1; IGF-1; insulin-like growth factor 1; insulin-like growth factor I; Somatomedin C; somatomedin-C	Mouse	E. coli
IGF-I/IGF-1 Protein, Mouse (His) is a mitogenic cytokine, binds to IGF type 1 receptor, and modulates growth in many tissues, such as nervous tissue, lymphoid tissue, reproductive tissue, smooth muscle, endothelium, and bone. IGF1 also mediates neuroprotective mechanism.

HY-P70698A

IGF-I/IGF-1 Protein, Mouse (N-His) IGF1; IGF-1; insulin-like growth factor 1; insulin-like growth factor I; Somatomedin C; somatomedin-C	Mouse	E. coli
IGF-I/IGF-1 Protein, Mouse (His) is a mitogenic cytokine, binds to IGF type 1 receptor, and modulates growth in many tissues, such as nervous tissue, lymphoid tissue, reproductive tissue, smooth muscle, endothelium, and bone. IGF1 also mediates neuroprotective mechanism.

HY-P73906

IGF2 Protein, Human (P.pastoris)
insulin-like growth factor II; IGF-II; Preptin; IGF2; PP1446
Human P. pastoris
HY-P76410

IGFBP-5 Protein, Canine (HEK293, Fc)
insulin-like growth factor-binding protein 5; IGFBP5
Canine HEK293
HY-P77395

IGFL2 Protein, Human (HEK293, Fc)
insulin growth factor-like family member 2; IGFL2
Human HEK293

HY-P72256

IGF-I R Protein, Human (His) CD221; CD221 antigen ; IGF 1 receptor; IGF 1R; IGF I receptor; IGF-I receptor; Igf1r; IGF1R_HUMAN; IGFIR; IGFIRC; IGFR; insulin like growth factor 1 receptor; insulin like growth factor 1 receptor precursor; insulin-like growth factor 1 receptor beta chain; insulin-like growth factor I receptor; JTK13; MGC142170; MGC142172; MGC18216; Soluble IGF1R variant 1; Soluble IGF1R variant 2	Human	E. coli

HY-P74848

IGFBP-1 Protein, Rhesus Macaque (HEK293, His)
insulin-like growth factor-binding protein 1; IGFBP1
Rhesus Macaque HEK293
HY-P700241AF

Animal-Free IGF-I Protein, Pig (His)
insulin-like growth factor I; IGF-I; MGF; Somatomedin-C; IBP1
Pig E. coli
HY-P74843

IGF-I/IGF-1 Protein, Mouse (P.pastoris)
insulin-like growth factor I; IGF-I; MGF; Somatomedin-C; IBP1
Mouse P. pastoris
HY-P74849

IGFBP-1 Protein, Canine (HEK293, His)
insulin-like growth factor-binding protein 1; PP12; IBP-1
Canine HEK293
HY-P73136

IGF-I/IGF-1 Protein, Human (HEK293, hFc)
insulin-like growth factor I; IGF-I; MGF; Somatomedin-C; IBP1
Human HEK293
HY-P73140

IGFBP-5 Protein, Human (sf9, His)
insulin-like growth factor-binding protein 5; IBP-5; IGFBP-5; IBP5
Human Sf9 insect cells
HY-P73141

IGFBP-6 Protein, Human (HEK293, His)
insulin-like growth factor-binding protein 6; IBP-6; IGFBP-6; IBP6
Human HEK293
HY-P73142

IGFBP-7 Protein, Human (HEK293, Fc)
insulin-like growth factor-binding protein 7; IGFBP7; TAF; MAC25; PSF
Human HEK293
HY-P70783G

GMP IGF-I/IGF-1 Protein, Human (E51R)
insulin-like growth factor I; IGF-I; MGF; Somatomedin-C; IBP1
Human E. coli
HY-P73905

IGFBP-6 Protein, Rat (HEK293, His)
insulin-like growth factor-binding protein 6; IBP-6; IGFBP-6; IBP6
Rat HEK293
HY-P77394

IGFBP-5 Protein, Cynomolgus (HEK293, His)
insulin-like growth factor-binding protein 5; IBP-5; IGFBP-5; IBP5
Cynomolgus HEK293
HY-P73138

IGFBP-3 Protein, Human (HEK293, His)
insulin-like growth factor-binding protein 3; IGF-BP3; IBP-3; IGFBP-3
Human HEK293
HY-P74844

IGFBP-7 Protein, Mouse (HEK293, Fc)
IBP-7; IGFBP7; IGFBP-7v; insulin-like growth factor binding protein 7
Mouse HEK293
HY-P74845

IGFBP-4 Protein, Mouse (HEK293, His)
BP-4; HT29-IGFBP; IBP4; insulin-like growth factor-binding protein 4
Mouse HEK293
HY-P74846

IGFBP-2 Protein, Mouse (HEK293, His)
IBP-2; insulin-like growth factor binding protein 2; IGFBP2; IGF-BP53
Mouse HEK293
HY-P74847

IGFBP-2 Protein, Mouse (HEK293, Fc)
IBP-2; insulin-like growth factor binding protein 2; IGFBP2; IGF-BP53
Mouse HEK293

HY-P70357

IGFBP-6 Protein, Mouse (HEK293, His) rMuinsulin-like growth factor-binding protein 6/IGFBP-6, His; insulin-like growth factor-binding protein 6; IBP-6; IGF-binding protein 6; IGFBP-6; Igfbp6; IBP6; IGF binding protein 6; insulin-like growth factor-binding protein 6	Mouse	HEK293

HY-P73137

IGF-I R Protein, Human (sf9, His-GST)
insulin-like growth factor 1 receptor; IGF-I receptor; CD221; IGF1R
Human Sf9 insect cells
HY-P77393

IGFBP-4 Protein, Cynomolgus (HEK293, His)
insulin-like growth factor-binding protein 4; IGF-BP-4; IBP-4; IGFBP-4; BP4
Cynomolgus HEK293
HY-P70787

IGF-I/IGF-1 Protein, Human (67a.a)
insulin-Like Growth Factor I; IGF-I; Mechano Growth Factor; MGF; Somatomedin-C; IGF1; IBP1
Human E. coli
HY-P70788

IGF-I/IGF-1 Protein, Human (G49-A118)
insulin-Like Growth Factor I; IGF-I; Mechano Growth Factor; MGF; Somatomedin-C; IGF1; IBP1
Human E. coli
HY-P72606

IGF-I R Protein, Human (902a.a, HEK293, His)
insulin-like growth factor 1 receptor; IGF-I receptor; IGF1R; CD221
Human HEK293
HY-P74442

IGF-I R Protein, Human (932a.a, HEK293, His)
insulin-like growth factor 1 receptor; IGF-I receptor; CD221; IGF1R
Human HEK293
HY-P700256

IGFBP-1 Protein, Mouse (SUMO, His)
insulin-like growth factor-binding protein 1; IBP-1; IGF-binding protein 1; IGFBP-1; PP12
Mouse E. coli
HY-P700478

IGF-I/IGF-1 Protein, Human (P. pastoris, N-His)
insulin-Like Growth Factor I; IGF-I; Mechano Growth Factor; MGF; Somatomedin-C; IGF1; IBP1
Human P. pastoris
HY-P72608

IGFBP-1 Protein, Human (HEK293, His)
insulin-like growth factor-binding protein 1; IBP-1; IGF-binding protein 1; IGFBP-1; PP12
Human HEK293
HY-P73139

IGFBP-4 Protein, Human (258a.a, HEK293, His)
insulin-like growth factor-binding protein 4; IGF-BP-4; IBP-4; IGFBP-4; BP4
Human HEK293
HY-P70783

IGF-I/IGF-1 Protein, Human (70a.a, E51R)
insulin-Like Growth Factor I; IGF-I; Mechano Growth Factor; MGF; Somatomedin-C; IGF1; IBP1
Human E. coli
HY-P76409

IGFBP-2 Protein, Rhesus Macaque (HEK293, His)
insulin-like growth factor 2 mRNA-binding protein 2; IMP-2; IGF2BP2; VICKZ2
Rhesus Macaque HEK293
HY-P700093AF

Animal-Free IGF-I/IGF-1 Protein, Human (His)
Somatamedin C; IGF-IA; insulin-Like Growth Factor I; IGF-I; Mechano Growth Factor; MGF; Somatomedin-C; IGF1; IBP1
Human E. coli
HY-P72607

IGFBP-4 Protein, Human (237a.a, HEK293, His)
insulin-Like Growth Factor-Binding Protein 4; IBP-4; IGF-Binding Protein 4; IGFBP-4; IBP4
Human HEK293
HY-P74850

IGF2BP2 Protein, Human (sf9, His-GST)
insulin-like growth factor 2 mRNA-binding protein 2; IMP-2; IGF2BP2; VICKZ2
Human Sf9 insect cells
HY-P700486

IGFBP-1 Protein, Mouse (P. pastoris, N-His)
Igfbp1; Igfbp-1; insulin-like growth factor-binding protein 1; IBP-1; IGF-binding protein 1; IGFBP-1
Mouse P. pastoris
HY-P72378

IGFBP-5 Protein, Human (Biotinylated, HEK293, His-Avi)
insulin-Like Growth Factor-Binding Protein 5; IBP-5; IGF-Binding Protein 5; IGFBP-5; IGFBP5; IBP5
Human HEK293
HY-P70726

IGFBP-7 Protein, Human (HEK293, His)
insulin-like growth factor-binding protein 7; IGFBP7; IGF-binding protein 7; IGFBP-rP1; MAC25 protein; Tumor-derived adhesion factor; TAF
Human HEK293
HY-P70858

IGFBP-7 Protein, Mouse (HEK293, His)
insulin-like growth factor-binding protein 7; IGFBP7; IGF-binding protein 7; IGFBP-rP1; MAC25 protein; Tumor-derived adhesion factor; TAF
Mouse HEK293

HY-P70408

IGFBP-5 Protein, Mouse (HEK293, His) rMuinsulin-like growth factor-binding protein 5/IGFBP5, His; BP-5; IGFBP-5; IGF-binding protein 5; insulin-like growth factor-binding protein 5;	Mouse	HEK293

HY-P70602

CCN2/CTGF Protein, Human (HEK293, Fc) Connective tissue growth factor; CCN family member 2; Hypertrophic chondrocyte-specific protein 24; insulin-like growth factor-binding protein 8; CTGF; IGFBP8	Human	HEK293

HY-P7842

CCN1/Cyr61 Protein, Human (HEK293, Fc) rHuCCN family member 1/Cyr61, Fc; Protein CYR61; CCN family member 1; Cysteine-rich angiogenic inducer 61; insulin-like growth factor-binding protein 10 ; GIG1; CYR61; CCN1; IGFBP10;	Human	HEK293

HY-P70106

CCN2/CTGF Protein, Human (HEK293) rHuConnective tissue growth factor/CTGF; Connective tissue growth factor; CCN family member 2; Hypertrophic chondrocyte-specific protein 24; insulin-like growth factor-binding protein 8; IBP-8; IGF-binding protein 8; IGFBP-8	Human	HEK293

HY-P70950

IGF2BP2 Protein, Human (T7-His) insulin-Like Growth Factor 2 mRNA-Binding Protein 2; IGF2 mRNA-Binding Protein 2; IMP-2; Hepatocellular Carcinoma Autoantigen p62; IGF-II mRNA-Binding Protein 2; VICKZ Family Member 2; IGF2BP2; IMP2; VICKZ2	Human	E. coli

HY-P70415

EIF4EBP1 Protein, Human (His) rHuEukaryotic translation initiation factor 4E-binding protein 1/EIF4EBP1, His; Eukaryotic Translation Initiation Factor 4E-Binding Protein 1; 4E-BP1; eIF4E-Binding Protein 1; Phosphorylated Heat- and Acid-Stable Protein Regulated by insulin 1; PHAS-I; EIF4EBP1	Human	E. coli

Cat. No.	Product Name

HY-15209S

Repaglinide D5

Repaglinide-d₅ is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].

HY-B0422S

Nateglinide D5
Nateglinide-d₅ is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].

HY-110228

Metformin-d6 hydrochloride
Metformin-d₆ (hydrochloride)e is a deuterium labeled Metformin hydrochloride. Metformin hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin hydrochloride triggers autophagy[1].

HY-U00462S

D-Mannoheptulose-13C
D-Mannoheptulose-¹³C is the ¹³C labeled D-Mannoheptulose. D-Mannoheptulose is a major non-structural carbohydrate in avocado. D-mannoheptulose is a specific inhibitor of D-glucose phosphorylation. D-Mannoheptulose can block insulin release and utilization

HY-100713S

Temocapril-d5
Temocapril-d₅ is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases[1][2].

HY-15494S1

Picropodophyllin-d6
Picropodophyllin-d₆ (AXL1717-d₆) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-15656S

Ceritinib D7

Ceritinib-d₇ is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

HY-N9410S

Lysophosphatidylcholine 18:2-d9
Lysophosphatidylcholine 18:2-d₉ is deuterium labeled Lysophosphatidylcholine 18:2. Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary

HY-W009204S5

Fmoc-Ala-OH-13C3
Fmoc-Ala-OH-¹³C₃ is a ¹³C-labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-ind

HY-101064S1

Fmoc-leucine-13C6,15N
Fmoc-leucine-¹³C₆,¹⁵N is a ¹⁵N-labeled and ¹³C-labled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity

HY-101064S3

Fmoc-leucine-d10
Fmoc-leucine-d₁₀ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1].

HY-101064S2

Fmoc-leucine-d3
Fmoc-leucine-d₃ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1].

Cat. No.	Product Name	Application	Reactivity

HY-P80190

Insulin Mouse mAb
WB, IHC-P, ELISA Human

Mouse Monoclonal Antibody to Insulin
HY-P80191

Insulin degrading enzyme Rabbit mAb
WB, IHC-P Human, Mouse

Rabbit Monoclonal Antibody to Insulin degrading enzyme / IDE
HY-P80192

Insulin Receptor Beta Rabbit mAb
WB, ICC/IF Human, Rat

Rabbit Monoclonal Antibody) to Insulin Receptor beta
HY-P80193

Insulin Receptor R Rabbit mAb
WB, IHC-P Human, Mouse

Rabbit Monoclonal Antibody to Insulin Receptor alpha

HY-P80717

IGF1 Receptor Rabbit mAb IGF1R; insulin-like growth factor 1 receptor; insulin-like growth factor I receptor; IGF-I receptor; CD antigen CD221	WB, IHC-P	Human
Rabbit Monoclonal Antibody to IGF1 Receptor

HY-P80825

Phospho-IGF1 Receptor (Tyr1166) Rabbit mAb IGF1R; insulin-like growth factor 1 receptor; insulin-like growth factor I receptor; IGF-I receptor; CD antigen CD221	WB, IP	Human, Mouse, Rat
Rabbit Monoclonal Antibody to IGF1 Receptor ( Phospho Tyr1166)

HY-P80689

Glucose Transporter GLUT4 Rabbit pAb SLC2A4; GLUT4; Solute carrier family 2; facilitated glucose transporter member 4; Glucose transporter type 4; insulin-responsive; GLUT-4	WB, IHC-P, ELISA	Human, Mouse, Rat
Rabbit Polyclonal Antibody to Glucose Transporter GLUT4 (phospho S488)

HY-P80850

Phospho-RSK2 (Ser227) Rabbit mAb RPS6KA3; ISPK1; MAPKAPK1B; RSK2; Ribosomal protein S6 kinase alpha-3; S6K-alpha-3; 90 kDa ribosomal protein S6 kinase 3; p90-RSK 3; p90RSK3; insulin-stimulated protein kinase 1; ISPK-1; MAP kinase-activated protein kinase 1b; MAPK-activated	WB, IP	Human, Mouse, Rat
Rabbit Monoclonal Antibody to Rsk 2 / MAPKAP Kinase 1b (phospho S227)

HY-P80724

IMP3 Rabbit pAb Cancer/testis antigen 98; CT98; DKFZp686F1078; hKOC; IF2B3_HUMAN; IGF II mRNA binding protein 3; IGF-II mRNA-binding protein 3; IGF2 mRNA binding protein 3; IGF2 mRNA-binding protein 3; IGF2BP3; IMP 3; IMP-3; insulin like growth factor 2 mRNA binding prot	WB, ICC/IF, IP, FC	Human, Mouse, Rat
Rabbit Polyclonal Antibody to IMP3

HY-P80526

4E BP1 Rabbit mAb EIF4EBP1; Eukaryotic translation initiation factor 4E-binding protein 1; 4E-BP1; eIF4E-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I	WB, IHC-P, IP	Human, Mouse, Rat, Hamster
Rabbit Monoclonal Antibody to 4E BP1

HY-P80786

Phospho-4E BP1 (Thr46) Rabbit mAb EIF4EBP1; Eukaryotic translation initiation factor 4E-binding protein 1; 4E-BP1; eIF4E-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I	WB, IHC-P, IP	Human, Mouse, Rat
Rabbit Monoclonal Antibody to eIF4EBP1 (phospho T37 + T46)

insulin

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products